Methods and materials for treating T-cell cancers

JP2023551535A5Inactive Publication Date: 2024-11-29JOHNS HOPKINS UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023533230
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-12-01
Filing Date
2021-12-01
Publication Date
2024-11-29
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for T-cell cancers, such as T-cell lymphoma and acute lymphoblastic leukemia, have poor outcomes due to the lack of targeted therapies that can selectively deplete malignant T cells without causing significant immunosuppression by depleting healthy T cells.

Method used

Development of bispecific antibodies that target specific subsets of T-cell receptor (TCR) antigens, such as TRBV5-5 and TRBV12, to stimulate healthy T cells to specifically lyse malignant T cells, using antigen-binding domains like single chain variable fragments (scFv) to bind to TRBV polypeptides and T cell co-receptor polypeptides like CD3.

Benefits of technology

These bispecific antibodies effectively reduce cancer cells by at least 95% and improve survival times in mammals by preserving normal T cells, offering a targeted therapeutic approach for T-cell cancers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000047_0000
    Figure 00000047_0000
  • Figure 00000047_0001
    Figure 00000047_0001
  • Figure 00000047_0002
    Figure 00000047_0002
Patent Text Reader

Abstract

This document relates to methods and materials for treating T-cell cancer.For example, the composition containing one or more bispecific molecules can be administered to a mammal with T-cell cancer to treat the mammal.For example, methods and materials are provided for using one or more bispecific molecules to treat a mammal with T-cell cancer.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Patent Application No. 63 / 119,753, filed December 1, 2020. The disclosure of the prior application is considered part of (and is incorporated by reference into) the disclosure of this application.

[0002] Federal Funding Statement This invention was made with government support under Grant Nos. CA009071, AR048522, CA006973, CA062924, GM007309 and CA230400 awarded by the National Institutes of Health. The government has certain rights in this invention.

[0003] Sequence Listing This document contains a Sequence Listing that has been submitted electronically as an ASCII text file named 44807-0384WO_SL_ST25.txt. The ASCII text file, created on November 30, 2021, is 335 kilobytes in size. The contents of this ASCII text file are incorporated herein by reference in their entirety.

[0004] 1. Technical Field This document relates to methods and materials for treating T-cell cancer.For example, a composition containing one or more bispecific molecules can be administered to a mammal with T-cell cancer to treat the mammal.For example, this document provides methods and materials for using one or more bispecific molecules to treat a mammal with T-cell cancer. [Background technology]

[0005] 2. Background information T-cell cancers are a heterogeneous group of malignancies that include approximately 15% non-Hodgkin's lymphomas (Swerdlow et al., Blood 127:2375-2390 (2016)) and 20% acute lymphoblastic leukemias (ALL; Han et al., Cancer Causes & Control 19:841-858 (2008); and Dores et al., Blood 119:34-43 (2012)). Treatment outcomes for T-cell lymphoma and relapsed T-cell ALL (T-ALL) are worse than those for comparable B-cell malignancies, with estimated 5-year survival rates of only 32% for T-cell lymphoma (Weisenburger et al., Blood 117:3402-3408 (2011)) and 7% for relapsed T-ALL (Fielding et al., Blood 109:944-950 (2007)).

[0006] Malignant B cells or T cells do not express cell surface antigens distinct from their noncancerous counterparts. Several targeted immunotherapeutic agents for B cell malignancies targeting pan-B cell antigens, such as CD19 or CD20, are feasible because the associated normal B cell aplasia is clinically well tolerated. However, similar strategies targeting pan-T cell antigens are not feasible because the resulting T cell depletion leads to clinically unacceptable levels of immunosuppression. [Prior art documents] [Non-patent literature]

[0007] [Non-Patent Document 1] Swerdlow et al., Blood 127:2375-2390 (2016) [Non-patent document 2] Han et al., Cancer Causes & Control 19:841-858 (2008) [Non-patent document 3] Dores et al., Blood 119:34-43 (2012) [Non-patent document 4] Weisenburger et al., Blood 117:3402-3408 (2011) [Non-Patent Document 5] Fielding et al., Blood 109:944-950 (2007) Summary of the Invention

[0008] overview This document provides methods and materials for treating T-cell cancer. In some cases, this document provides bispecific molecules that can be used to treat T-cell cancer. For example, a mammal (e.g., a human) with T-cell cancer can be treated using a bispecific molecule comprising at least two antigen-binding domains, where a first antigen-binding domain (e.g., a first single-chain variable fragment (scFv)) can bind to a T-cell receptor beta chain variable (TRBV) polypeptide and a second antigen-binding domain (e.g., a second scFv) can bind to a T-cell co-receptor polypeptide. In some cases, this document provides methods for treating T-cell cancer. For example, one or more bispecific molecules provided herein (e.g., a composition containing one or more bispecific molecules provided herein) can be administered to a mammal with T-cell cancer to treat the mammal.

[0009] As demonstrated herein, T-cell cancers can be treated by targeting specific subsets of T-cell receptor (TCR) antigens. For example, bispecific antibodies targeting TRBV5-5 and CD3 stimulate healthy T cells to express TRBV5-5. + Similarly, bispecific antibodies targeting TRBV12 and CD3 can stimulate healthy T cells to specifically lyse malignant T cells. +It can specifically lyse malignant T cells. Also, as demonstrated herein, bispecific antibodies targeting TRBV5-5 and CD3 and bispecific antibodies targeting TRBV12 and CD3 can preserve the majority of normal T cells in mammals and improve survival.

[0010] VDJ recombination, accompanied by allelic exclusion, leads to the expression of one of 30 T cell receptor beta chain variable (TRBV) polypeptides on the surface of each T cell, resulting in each TRBV being expressed on the surface of 1-5% of normal human peripheral blood T cells. In contrast, clonal T cell cancers express a single TRBV polypeptide. The ability to treat T cell cancers as described herein (e.g., by administering one or more bispecific molecules comprising a first antigen-binding domain capable of binding to a TRBV polypeptide and a second antigen-binding domain capable of binding to a T cell co-receptor polypeptide) offers a unique and yet unrealized opportunity to selectively deplete clonal T cell cancers while sparing the majority of normal T cells (see, e.g., Figure 1A). Additionally, the bispecific molecules provided herein (e.g., bispecific molecules comprising a first antigen-binding domain capable of binding to a TRBV polypeptide and a second antigen-binding domain capable of binding to a T cell co-receptor polypeptide) can be used as cost-effective, off-the-shelf targeted therapeutics for T cell cancers.

[0011] In general, one aspect of this document features a bispecific molecule including a first polypeptide including a first antigen-binding domain capable of binding to a TRBV polypeptide and a second polypeptide including a second antigen-binding domain capable of binding to a T cell co-receptor polypeptide. The first polypeptide can be a single-chain variable fragment (scFv), an antigen-binding fragment (Fab), an F(ab')2 fragment, or a biologically active fragment thereof. TRBV polypeptides include TRBV2 polypeptides, TRBV3-1 polypeptides, TRBV4-1 polypeptides, TRBV4-2 polypeptides, TRBV4-3 polypeptides, TRBV5-1 polypeptides, TRBV5-4 polypeptides, TRBV5-5 polypeptides, TRBV5-6 polypeptides, TRBV5-8 polypeptides, TRBV6-1 polypeptides, TRBV6-2 polypeptides, TRBV6-3 polypeptides, TRBV6-4 polypeptides, TRBV6-5 polypeptides, TRBV6-6 polypeptides, TRBV6-8 polypeptides, TRBV6-9 polypeptides, TRBV7-2 polypeptides, TRBV7-3 polypeptides, TRBV7-4 polypeptides, TRBV7-6 polypeptides, and TRBV7-7 polypeptides. The TRBV polypeptide may be a TRBV7-8 polypeptide, a TRBV7-9 polypeptide, a TRBV9 polypeptide, a TRBV10-1 polypeptide, a TRBV10-2 polypeptide, a TRBV10-3 polypeptide, a TRBV11-1 polypeptide, a TRBV11-2 polypeptide, a TRBV11-3 polypeptide, a TRBV12-2 polypeptide, a TRBV12-3 polypeptide, a TRBV12-4 polypeptide, a TRBV12-5 polypeptide, a TRBV13 polypeptide, a TRBV14 polypeptide, a TRBV15 polypeptide, a TRBV16 polypeptide, a TRBV18 polypeptide, a TRBV19 polypeptide, a TRBV20-1 polypeptide, a TRBV24-1 polypeptide, a TRBV25-1 polypeptide, a TRBV27 TRBV28 polypeptide, a TRBV29-1 polypeptide, or a TRBV30 polypeptide. For example, the TRBV polypeptide may be a TRBV5-5 polypeptide. The first antigen-binding domain capable of binding to the TRBV5-5 polypeptide has the amino acid sequence shown in SEQ ID NO: 1. LCDR1, V having the amino acid sequence shown in SEQ ID NO:2 L CDR2, and V having the amino acid sequence shown in SEQ ID NO:3 L and a V having the amino acid sequence set forth in SEQ ID NO:4. H CDR1, V having the amino acid sequence shown in SEQ ID NO:5 H CDR2, and V having the amino acid sequence shown in SEQ ID NO:6 H The TRBV polypeptide may comprise a heavy chain comprising a CDR3. In some cases, the light chain may comprise the amino acid sequence shown in SEQ ID NO:7, and the heavy chain may comprise the amino acid sequence shown in SEQ ID NO:8. In some cases, the light chain may comprise the amino acid sequence shown in SEQ ID NO:38, and the heavy chain may comprise the amino acid sequence shown in SEQ ID NO:39. For example, the TRBV polypeptide may be a TRBV12 polypeptide. The first antigen-binding domain capable of binding to a TRBV12 polypeptide may comprise a V having the amino acid sequence shown in SEQ ID NO:9. L CDR1, V having the amino acid sequence shown in SEQ ID NO:10 L CDR2, and V having the amino acid sequence shown in SEQ ID NO:11 L and a V having the amino acid sequence set forth in SEQ ID NO: 12. H CDR1, V having the amino acid sequence shown in SEQ ID NO:13 H CDR2, and V having the amino acid sequence shown in SEQ ID NO: 14 HThe second polypeptide may comprise a heavy chain comprising a CDR3. In some cases, the light chain may comprise the amino acid sequence set forth in SEQ ID NO:15, and the heavy chain may comprise the amino acid sequence set forth in SEQ ID NO:16. In some cases, the light chain may comprise the amino acid sequence set forth in SEQ ID NO:40, and the heavy chain may comprise the amino acid sequence set forth in SEQ ID NO:41. The second polypeptide may be an scFv, Fab, F(ab')2 fragment, or a biologically active fragment thereof. The T cell co-receptor polypeptide may be a cluster of differentiation 3 (CD3) polypeptide or a T cell receptor polypeptide. The second antigen-binding domain capable of binding to a CD3 polypeptide may be a V having the amino acid sequence set forth in SEQ ID NO:17. L CDR1, V having the amino acid sequence shown in SEQ ID NO:18 L CDR2, and V having the amino acid sequence shown in SEQ ID NO:19 L and a V having the amino acid sequence set forth in SEQ ID NO:20. H CDR1, V having the amino acid sequence shown in SEQ ID NO:21 H CDR2, and V having the amino acid sequence shown in SEQ ID NO:22 H In some cases, the light chain may comprise the amino acid sequence set forth in SEQ ID NO:23 and the heavy chain may comprise the amino acid sequence set forth in SEQ ID NO:24.

[0012] In another aspect, this document features a method for treating a mammal with T-cell cancer. The method can include, or can essentially consist of, administering to the mammal with T-cell cancer a bispecific molecule comprising a first polypeptide having a first antigen-binding domain capable of binding to a TRBV polypeptide and a second polypeptide having a second antigen-binding domain capable of binding to a T-cell co-receptor polypeptide. The mammal can be a human. The T-cell cancer can be a clonal T-cell cancer. The T-cell cancer can be acute lymphoblastic leukemia (ALL), peripheral T-cell lymphoma (PTCL), angioimmunoblastic T-cell lymphoma (AITL), T-cell prolymphocytic leukemia (T-PLL), adult T-cell leukemia / lymphoma (ATLL), enteropathy-associated T-cell lymphoma (EATL), monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), follicular T-cell lymphoma (FTCL), nodal peripheral T-cell lymphoma (nodal PTCL), cutaneous T-cell lymphoma (CTCL), anaplastic large cell lymphoma (ALCL), T-cell large granular lymphocyte leukemia (T-LGL), extranodal NK / T-cell lymphoma (NKTL), or hepatosplenic T-cell lymphoma. The cancer cells in the mammal can be reduced by at least 95 percent. The method can be effective to improve the survival time of the mammal (eg, can be effective to improve the survival time of the mammal by at least 37.5 percent).

[0013] In another aspect, this document features a method for treating a mammal with celiac disease. The method can include, or consist essentially of, administering to a mammal with celiac disease a bispecific molecule comprising a first polypeptide having a first antigen-binding domain capable of binding to a TRBV polypeptide and a second polypeptide having a second antigen-binding domain capable of binding to a T cell co-receptor polypeptide. The mammal can be a human. The TRBV polypeptide can be a TRBV4 polypeptide, a TRBV6 polypeptide, a TRBV7 polypeptide, a TRBV9 polypeptide, a TRBV20 polypeptide, or a TRBV29 polypeptide, and the T cell co-receptor polypeptide can be a CD3 polypeptide. The TRBV polypeptide can be a TRBV6-1 polypeptide, a TRBV7-2 polypeptide, a TRBV9-1 polypeptide, a TRBV20-1 polypeptide, or a TRBV29-1 polypeptide, and the T cell co-receptor polypeptide can be a CD3 polypeptide.

[0014] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this invention belongs.Methods and materials similar or equivalent to those described herein can be used to implement the present invention, but suitable methods and materials are described below.All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety.In case of conflict, the present specification, including definitions, will prevail.In addition, materials, methods, and examples are only illustrative and are not intended to be limiting.

[0015] The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims. [Brief explanation of the drawings]

[0016] [Figure 1-1]Figures 1A-1E: TRBV-specific BsAbs deplete cognate TRBV-expressing T cells while sparing the majority of non-target T cells. Figure 1A: Schematic depicting the proposed selective TRBV depletion strategy: Human T cells contain 30 TRBV families; TRBV1: orange, TRBV5: red, TRBV12: cyan, TRBV20: green, and TRBV30: purple cells. α-V12 binds to TRBV12-expressing T cells, leading to selective killing of the TRBV12 population while sparing the majority of remaining non-TRBV12 T cells. Figure 1B: α-V5, α-V12, and α-C1 BsAbs are composed of α-CD3 scFv (orange) linked to α-TRBV5-5 (red), α-TRBV12 (cyan), and α-TRBC1 (gray) scFvs, respectively. Each scFv consists of a variable heavy chain (VH) and a variable light chain (VL). Figures 1C-1E: 1 x 10 normal human T cells were incubated with α-C1, α-V5, or α-V12 BsAb (0.5 ng / ml) for 17 hours, followed by counting the number of viable T cells and flow cytometric evaluation of TRBC and TRBV distribution among viable T cells. Data are shown as the average viable cell count from five different normal individuals. See also Figure 8. [Figure 1-2] See description of Figure 1-1. [Figure 1-3] See description of Figure 1-1. [Figure 2-1]Figures 2A-2I: TRBC1, TRBV5-5, or TRBV12 engagement activates T cells. Figure 2A: Schematic depicting bidirectional T cell killing by α-C1, α-V5, and α-V12 BsAbs. The conventional mechanism of action of α-C1, α-V5, and α-V12 involves crosslinking of a T cell-activating CD3 molecule (using α-CD3 scFv) on T cell #1 with TRBC1 (using α-C1), TRBV5-5 (using α-V5), or TRBV12 (using α-V12) on T cell #2 (e.g., a cancer cell), resulting in T cell #1-mediated killing of cell #2 ("1"). If the target cell (cell #2) is also a T cell and can be activated by cross-linking with α-C1, α-V5, or α-V12, cell #2 will function as an "effector" T cell and be able to kill T cell #1 ("2"). Figure 2B: Cartoon of α-CD3-CD19, α-C1-CD19, α-V5-CD19, and α-V12-CD19 BsAbs, which are composed of anti-CD19 scFv (black) linked to anti-CD3 (orange), anti-C1 (gray), anti-TRBV5 (red), and anti-TRBC1 (gray) scFvs. Figure 2C: Schematic showing that α-V12-CD19 BsAb cross-links TRBV12 on T cells with CD19 on NALM6 B cells, triggering T cell-mediated NALM6 B cell killing. Figures 2D and 2E: 5 × 10 normal human T cells were incubated with 5 × 10 wild-type (WT) or CD19 knockout (CD19-KO) NALM6 B cells (expressing luciferase) and the indicated BsAbs (0.5 ng / ml) for 17 hours. Normal human T cell activation was assessed using an IFNγ ELISA (Figure 2D), and live NALM6 B cells were assessed using luminescence (Figure 2E). In (Figure 2D) and (Figure 2E), bars represent the mean ± standard error of the mean using three different normal human T cell types. ***P ≤ 0.001, ****P ≤ 0.0001 by one-way ANOVA with Dunnett's multiple comparison test.Figures 2F-2I: 5 x 10 target NALM6 B cells (expressing luciferase) were incubated with 5 x 10 normal human T cells, TRBV5- and TRBV12-depleted T cells (Figure 2F) and (Figure 2H), or TRBV5-enriched ("TRBV5+") or TRBV12-enriched ("TRBV12+") T cells (Figure 2G) and (Figure 2I) with the indicated BsAbs (0.5 ng / ml) for 17 hours. Normal human T cell activation was assessed using IFNγ detection (Figure 2F) and (Figure 2G). Viable NALM6 B cells were assessed using luminescence (Figure 2H) and (Figure 2I). In Figures 2F and 2H, bars represent the mean ± standard error of the mean using three different normal human T cell types. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. ns, not significant by two-tailed paired t-test. In Figures 2G and 2I, bars represent mean ± standard error of the mean from three different human T cell lines. ****P ≤ 0.0001 by one-way ANOVA followed by Sidak's multiple comparison test. [Figure 2-2] See description of Figure 2-1. [Figure 2-3] See description of Figure 2-1. [Figure 2-4] See description of Figure 2-1. [Figure 2-5] See description of Figure 2-1. [Figure 3-1]Figures 3A-3D: TRBV-specific BsAbs induce T cell cytokine responses against cancer cells in vitro. Figure 3A: 3.5 x 10 normal human T cells were incubated with 3.5 x 10 indicated target T cell cancer cell lines in the presence of α-C1, α-V5, or α-V12 (0.5 ng / ml) for 17 hours. Luminescence was used to assess live Jurkat cells (Figure 3A) and HPB-ALL cells (Figure 3B). Bars represent the mean ± standard error of the mean using three different normal human T cell lines. ****P ≤ 0.0001 by one-way ANOVA with Sidak's multiple comparison test. Figure 3B: 5 x 10 normal human T cells or TRBV5- or TRBV12-depleted normal T cells were incubated with 5 x 10 Jurkat cells or HPB-ALL cells in the presence of the indicated BsAbs (0.5 ng / ml) for 17 hours. T cell activation was then assessed by IFNγ ELISA. Bars represent mean ± standard error of the mean from three different human T cell lines. y, yes; n, no; **P ≤ 0.01. ***P ≤ 0.001. ns, not significant by one-way ANOVA with Sidak's multiple comparison test. (Figure 3C) and (Figure 3D) 5 × 10 human T cells were incubated with 5 × 10 HPB-ALL cells (Figure 3C) or Jurkat T cells (Figure 3D) in the presence of the indicated concentrations of α-V5 (Figure 3C) or α-V12 (Figure 3D) for 17 hours. T cell cytokine release was then measured by Luminex assay. The EC50 (M) for each analyte is displayed on the corresponding graph. Data are shown as mean ± standard error of the mean from three different human T cell lines. [Figure 3-2] See description of Figure 3-1. [Figure 4-1]Figures 4A-4F: TRBV-specific BsAbs kill T-cell cancer cells in vitro. Figures 4A and 4B: 5 x 10 human T cells were incubated with 5 x 10 Jurkat cells (Figure 4A) or HPB-ALL cells (Figure 4B) for 17 hours in the presence of the indicated concentrations of α-V12 (Figure 4A) or α-V5 (Figure 4B). Jurkat and HPB-ALL cells expressed luciferase. Luminescence was used to assess viable Jurkat and HPB-ALL cells. The EC50 (M) for each BsAb is shown in the corresponding graph. Data are shown as the mean ± standard error of the mean using triplicate normal human T cell lines. Figure 4C: 5 × 10 normal human T cells were incubated with 5 × 10 wild-type (WT) or TCR gene-disrupted (TCR-KO) Jurkat cells for 17 hours in the presence of the indicated BsAbs (0.5 ng / ml). Figure 4D: The same experiment was performed using WT or TCR-KO HPB-ALL cells. All Jurkat and HPB-ALL cells expressed GFP. CD3 and GFP expression was then assessed using flow cytometry. In Figures 4C and 4D, the numbers next to the density plots indicate the percentage of viable cells. Figures 4E and 4F show aggregate data for the percentage of tumor cells in each treatment condition using T cells from three different human donors. Bars represent the mean ± standard error of the mean. ****P ≤ 0.0001. ns, not significant by ANOVA followed by Sidak's multiple comparison test. See also Figure 12. [Figure 4-2] See description of Figure 4-1. [Figure 4-3] See description of Figure 4-1. [Figure 5-1]Figures 5A-5F: TRBV-specific BsAbs kill patient-derived T-ALL cells in vitro. Figure 5A: Flow cytometry analysis of two T-ALL patient samples with circulating lymphoblasts expressing TRBV12. The numbers immediately adjacent to the plots indicate the percentage of CD3+ cells expressing TRBV12. Figures 5B and 5C: 5 × 104 normal human T cells were cocultured with 5 × 104 patient-derived T-ALL target cells for 17 hours in the presence of the indicated BsAbs (0.5 ng / ml). T cell activation was assessed by measuring IFNγ in the supernatant (for patients 1 and 2) (Figure 5B) or by flow cytometry analysis of the indicated T cell activation and exhaustion markers (for patient 1) (Figure 5C). Bars represent the mean ± standard error of the mean from three technical replicates. ****P ≤ 0.001 by one-way ANOVA followed by Dunnett's multiple comparison test. Figure 5D: Histogram of HLA-A3 staining of normal human T cells and patient-derived T-ALL malignant cells. Figure 5E and (Figure 5F): 5 × 10 normal human T cells were cocultured with 5 × 10 patient-derived T-ALL target cells for 17 hours in the presence of α-CD19 or α-V12 BsAb (0.5 ng / ml). Flow cytometric analysis of HLA-A3 and CD3 was then performed. Numbers immediately adjacent to the plots indicate the number of cells counted by flow cytometry in a representative experiment (Figure 5E), and data from three technical replicates are shown (Figure 5F). ****P≦0.0001 by one-way ANOVA with Tukey's multiple comparison test. [Figure 5-2] See description of Figure 5-1. [Figure 5-3] See description of Figure 5-1. [Figure 6A]Figures 6A-6H: TRBV-specific BsAb specifically kills cancer cells in vivo. Figures 6A-6C: NSG mice were intravenously injected with 5 x 10 normal human T cells and 5 x 10 wild-type or TCR-KO Jurkat cells. Identical experiments were performed using wild-type and TCR-KO HPB-ALL cells. All Jurkat and HPB-ALL cells expressed luciferase and GFP. Intraperitoneal pumps containing 100 μg of α-CD19, α-V12, or α-V5 BsAb were placed in the animals 4 days after cell injection, and BLI was performed on the indicated days. BLI data are representative of one of two independent experiments (Figure 6B) and (Figure 6C). Figure 6D: Integrated radiance values ​​were measured on the indicated days from two independent experiments using a total of 11 NSG mice in each group. **P ≤ 0.01, ****P ≤ 0.0001 by one-way ANOVA with Sidak's multiple comparison test. Figures 6E and 6F: Flow cytometry was used on mouse blood collected on day 19 to detect circulating WT Jurkat or HPB-ALL cells (CD3+, GFP+, upper right quadrant) or circulating TCR-KO Jurkat or HPB-ALL cells (CD3-, GFP+, lower right quadrant) or circulating normal human T cells (CD3+, GFP-, upper left quadrant) after the indicated treatments. Circulating cancer cell and T cell numbers were assessed from six different NSG mice for each cancer cell type. Data are shown as mean ± standard error of the mean. **P ≤ 0.01, ****P ≤ 0.0001 by one-way ANOVA with Tukey's multiple comparison test. Figures 6G and 6H: Kaplan-Meier survival curves for WT or TCR-KO Jurkat (Figure 6G) or HPB-ALL (Figure 6H)-bearing NSG mice after various treatments. Median overall survival (OS): Jurkat WT / α-CD19 = 36 days, Jurkat WT / α-V12 = 73 days, Jurkat TCR-KO / α-V12 = 46 days. Jurkat WT / α-CD19 vs. Jurkat WT / α-V12 hazard ratio (HR) = 0.18, ****P < 0.0001, log-rank (Mantel-Cox) test.Median OS: HPB-ALL WT / α-CD19 = 40 days, HPB-ALL WT / α-V5 = 64 days, HPB-ALL TCR-KO / α-V5 = 33 days. HPB-ALL WT / α-CD19 vs. HPB-ALL WT / α-V5, HR = 0.19, ****P = 0.0001, log-rank (Mantel-Cox) test. Survival data are compiled from two independent experiments. [Figure 6B] See legend to Figure 6A. [Figure 6C] See legend to Figure 6A. [Figure 6D] See legend to Figure 6A. [Figure 6E] See legend to Figure 6A. [Figure 6F] See legend to Figure 6A. [Figure 6G] See legend to Figure 6A. [Figure 6H] See legend to Figure 6A. [Figure 7A] Figures 7A-7E: Characterization of α-V12 and α-V5 BsAbs. Figure 7A: Coomassie blue staining and Western blot (using rabbit anti-6xHis and HRP-conjugated anti-rabbit antibodies) of purified α-V12 and α-V5 BsAbs. Figures 7B and 7C: Analytical chromatograms of purified α-V12 (Figure 7B) or α-V5 (Figure 7C) BsAbs are shown in black. Bovine serum albumin (BSA) chromatograms (control) are shown in red. The retention times of each analyte are indicated above the peaks. Figures 7D and 7E: Differential scanning fluorimetry analysis of α-V12 (Figure 7D) or α-V5 (Figure 7E) BsAbs showing the negative derivative of relative fluorescence units ("RFU") versus temperature ("Temp"). Melting temperatures correspond to the peak / maximum of the first derivative of the curves and are displayed on the corresponding graphs. [Figure 7B] See legend to Figure 7A. [Figure 7C] See legend to Figure 7A. [Figure 7D] See legend to Figure 7A. [Figure 7E] See legend to Figure 7A. [Figure 8-1]Figures 8A-8H: In vitro treatment of normal human T cells with TRBV- and TRBC-specific BsAb. Figures 8A and 8B: 1 x 10 normal human T cells were incubated with 0.5 ng / ml α-V5 or α-V12 BsAb (Figure 8A) or α-C1 (Figure 8B) for 17 hours, followed by counting the number of viable T cells and flow cytometry evaluation of TRBC and TRBV distribution among viable T cells. Graphs show cell counts using T cells from five different normal individuals (Figures 8A and 8B). Figure 8C: TRBV5+ flow-sorted T cells were stained with CellTrace Violet and mixed with TRBV5-depleted normal human T cells at a 1:10 ratio. T cells were then incubated with α-V5 BsAb for 17 hours, followed by flow cytometry. In a similar experiment, TRBV12+ flow-sorted T cells were stained with CellTrace Violet and mixed with TRBV12-depleted normal human T cells (1:10 ratio) followed by incubation with α-V12 BsAb. The experiment was repeated using three different normal human T cell donors. Figure 8D and Figure 8E: TRBC1 flow-sorted T cells were stained with CellTrace Violet and mixed with TRBC1-depleted normal human T cells at a 2:3 ratio. The T cells were then incubated with α-C1 BsAb for 17 hours, followed by flow cytometry analysis (Figure 8D) and viable cell counting (Figure 8E). Figures 8F-8H: 1 x 10 normal human T cells ("Normal"), or T cells depleted of TRBC1-expressing T cells (Figure 8F) or TRBV5- and TRBV12-expressing T cells (Figure 7G) ("Dep"), or TRBV5-enriched (TRBV5+) and TRBV12-enriched (TRBV12+) T cells (Figure 8H) were incubated for 17 hours with or without ("None") α-C1 (Figure 8D), α-V5, or α-V12 BsAb (Figure 8E) (0.5 ng / ml), followed by viability assessment. Bars in Figures 8F, 8G, and 8H represent the mean ± standard error of the mean using three different normal human T cell lines. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 by two-tailed paired t-test. ns, not significant. [Figure 8-2] See description of Figure 8-1. [Figure 8-3] See description of Figure 8-1. [Figure 8-4] See description of Figure 8-1. [Figure 9-1]Figures 9A-9E: TRBC1, TRBV5-5, or TRBV12 engagement activates T cells against NALM6 B cells. Figure 9A: 2 x 10 wild-type (WT), CD19-low, or CD19-knockout (CD19-KO) NALM6 B cells were stained with a human anti-CD19 antibody followed by flow cytometry. Also shown are WT NALM6 B cells stained with an isotype control antibody as a control. Figure 9B: 5 x 10 normal human T cells were incubated with 5 x 10 wild-type or CD19-KO NALM6 B cells and the indicated BsAbs (0.5 ng / ml) for 17 hours. Normal human T cell activation was assessed using IL-2, TNFα, and IL-10 ELISA. Bars represent the mean ± standard error of the mean using three different normal human T cell types. *P ≤ 0.05, ***P ≤ 0.0001 by one-way ANOVA followed by Dunnett's multiple comparison test. Figure 9C: 5 × 10 normal human T cells were incubated with the indicated BsAbs (0.5 ng / ml) in the presence or absence of 5 × 10 WT NALM6 B cells for 17 hours, followed by flow cytometry analysis of the indicated T cell activation and exhaustion markers. Bars represent the mean ± standard error of the mean using three different normal human T cell types. Histograms below each bar show data from one human T cell donor. *P ≤ 0.05, ***P ≤ 0.0001 by one-way ANOVA followed by Dunnett's multiple comparison test. Figures 9D and 9E: 5 x 10 normal human T cells were incubated with the indicated BsAbs (0.5 ng / ml) for 17 hours in the presence of 5 x 10 wild-type or CD19 low NALM6 B cells (expressing luciferase). Normal human T cell activation was assessed using an IFNγ ELISA (Figure 9D), and live NALM6 B cells were assessed using luminescence (Figure 9E). In Figures 9D and 9E, bars represent the mean ± standard error of the mean using three different human T cell types. ns, not significant by two-tailed unpaired t-test. [Figure 9-2] See description of Figure 9-1. [Figure 9-3] See description of Figure 9-1. [Figure 10-1] Figures 10A-10D: α-C1 BsAb kills both TRBC1+ and TRBC2+ expressing T cells. Figure 10A: Schematic of the α-C1 killing mechanism of TRBC2+ HPB-ALL cells. α-C1 crosslinks TRBC1+ T cells ("T") (using α-TRBC1 scFv) with HPB-ALL cells ("H") (using α-CD3 scFv), causing HPB-ALL cell death. Figure 10B: Normal human T cells ("non-depleted") or TRBC1-depleted T cells were stained with TRBC1 antibody and evaluated by flow cytometry. Histograms representative of three independent experiments are shown. Figures 10C and 10D: 5 × 10 normal human undepleted T cells or TRBC1-depleted ("TRBC1 dep") T cells were incubated with 5 × 10 Jurkat cells (TRBC1+) or HPB-ALL cells (TRBC2+) for 17 hours with or without α-C1 BsAb (0.5 ng / ml). T cell activation was assessed by measuring IFNγ in the supernatant (Figure 10C), and cancer cell killing was assessed by flow cytometry (Figure 10D). Jurkat cells ("J") and HPB-ALL cells ("H") are GFP+ and CD3+, while normal human T cells ("T") are GFP- and CD3+. Numbers within the plots indicate the percentage of surviving cells. Diagrams adjacent to the flow plots demonstrate the mechanism of α-C1 BsAb-mediated killing of target Jurkat and HPB-ALL cells. Non-depleted T cells can kill Jurkat cells by two mechanisms (denoted as "1" and "2"). Non-depleted T cells can kill HPB-ALL cells by only one mechanism (denoted as "2"). TRBC1-depleted T cells (consisting only of TRBC2 T cells) can continue to kill Jurkat cells using mechanism "1," whereas TRBC1-depleted T cells (or TRBC2 T cells) cannot kill HPB-ALL cells (Figure 10D). In Figure 10C, bars represent the mean ± standard error of the mean from three technical replicates. ***P ≤ 0.001. ns, not significant by one-way ANOVA with Tukey's multiple comparison test. [Figure 10-2] See description of Figure 10-1. [Figure 11] Figures 11A-11B: Cell surface CD3 and TRBV expression in T cell cancer cell lines. Figures 11A and 11B: 2 x 105 human T cell cancer-derived cell lines were stained with an isotype control antibody or human anti-CD3 (Figure 11A) or anti-TRBV5-5 and anti-TRBV12-specific antibodies (Figure 11B), followed by flow cytometry. Data are representative of two independent experiments. [Figure 12-1]Figures 12A-12F: TRBV-specific BsAbs activate healthy T cells and kill T cell cancer cells in vitro. 5 x 10 normal human T cells from two additional normal human individuals (donor 2 and donor 3) were incubated with 5 x 10 wild-type or TCR-KO Jurkat cells in the presence of the indicated BsAbs (0.5 ng / ml) for 17 hours. Identical experiments were performed with wild-type or TCR-KO HPB-ALL cells. Figure 12A: All Jurkat and HPB-ALL cells expressed GFP. CD3 and GFP expression was then assessed using flow cytometry. Numbers next to the density plots indicate the percentage of surviving cells. Figures 12B and 12C: 5 x 10 normal human T cells were incubated with 5 x 10 WT Jurkat cells (Figure 12B) or WT HPB-ALL cells (Figure 12C) with the indicated BsAbs (0.5 ng / ml) for 17 hours, followed by flow cytometry analysis of the indicated T cell activation and exhaustion markers. Bars represent the mean ± standard error of the mean using three different normal human T cell types. ***P < 0.0001 by one-way ANOVA with Dunnett's multiple comparison test. Figure 12D: Normal human T cells or CD4-depleted T cells were stained with anti-human CD4 or CD8 antibodies and evaluated by flow cytometry. Figure 12E: 5 × 10 normal human T cells or CD4-depleted T cells were incubated with 5 × 10 Jurkat or HPB-ALL cells (expressing luciferase) for 17 hours in the presence of α-CD19, α-V12 BsAb, or α-V5 (0.5 ng / ml). Luminescence was used to assess viable Jurkat or HPB-ALL cells. Bars represent the mean ± standard error of the mean using T cells from three different normal human individuals. ***P ≤ 0.0001 by two-tailed unpaired t-test. Figure 12F: α-V12 or αV-5 BsAb incubated with human serum for the indicated time points. BsAb activity was assessed by coculture of 5 × 10 normal human T cells with 5 × 10 Jurkat or HPB-ALL cells. The graph shows the percentage of live Jurkat or HPB-ALL cells after incubation with T cells from three different normal human individuals. [Figure 12-2] See description of Figure 12-1. [Figure 12-3] See description of Figure 12-1. [Figure 13A] Figures 13A-13B: TCRβ sequencing and target specificity to evaluate α-V12 and α-V5. Figures 13A and 13B: 1 × 10 normal human T cells and 1 × 10 Jurkat cells (Figure 13A) or 1 × 10 HPB-ALL cells (Figure 13B) were incubated with α-CD19 (green circles), α-V12 (blue squares) (Figure 13A), or α-V5 (orange squares) (Figure 13B) BsAb (0.5 ng / ml) for 17 hours. RNA was purified from the cells, and TCRβ sequencing was used to identify the TRBV family. Numbers represent the mean ± standard error of the mean of the percentage of TRBV distribution from three technical replicates. Black arrows indicate the TRBV12-3 signal from Jurkat cells and the TRBV5-5 signal from HPB-ALL cells. The numbers next to the arrows indicate the percentage of TRBV. Data are representative of two independent experiments. [Figure 13B] See legend to Figure 13A. [Figure 14A] Figures 14A-14C: TRBV5 family sequence alignment and structural analysis. Figures 14A and 14B: TRBV5 family phylogenetic tree (Figure 14A) and TRBV5 family sequence alignment (Figure 14B). Amino acid residues in bold are shared by all TRBV5 family members. Positions 20, 81, and 101 are highlighted in green, indicating residues common to TRBV5-5 and 5-6 but different in other TRBV5 members. Figure 14C: TRBV5-1 structure (cyan). The inset shows amino acid positions 81 (D in TRBV5-5 / 5-6 vs. G in 5-1 or P in 5-4 / 5-8) and 101 (L in TRBV5-5 / 5-6 vs. E in TRBV5-1 / 5-4 / 5-8) in stick form. TRBV5-5 / 5-6 are shown in yellow; TRBV5-1 / 5-4 / 5-8 are shown in dark blue. [Figure 14B] See legend to Figure 14A. [Figure 14C] See legend to Figure 14A. [Figure 15-1] Figures 15A-15I: TRBV-specific BsAbs activate human T cells and specifically kill T cell cancers in vivo at low E:T ratios. Figure 15A: Intraperitoneal pumps containing 100 μg of α-V12 or α-V5 BsAb were placed in three NSG mice on day 0, followed by daily mouse blood sampling and detection of the indicated BsAbs. Figures 15B and 15C: NSG mice were intravenously injected with 0.5 × 10 normal human T cells and 2.5 × 10 WT Jurkat or WT HPB-ALL cells. All Jurkat and HPB-ALL cells expressed luciferase and GFP. Intraperitoneal pumps containing 100 μg of α-CD19, α-V12, or α-V5 BsAb were placed in the animals 4 days after cell injection. Mouse blood sampling and BLI were performed on the indicated days. Figures 15D and 15E: Radiance values ​​in each group were measured on the indicated days. *P≦0.05, **P≦0.01 by unpaired, two-tailed t-test. Figures 15F and 15G: IFNγ and TNFα ELISA from mouse serum collected on days 3 and 6. Figures 15H and 15I: Flow cytometry on mouse blood collected on days 3 and 6 to detect activation or exhaustion markers on circulating normal human T cells. Data are shown as mean ± standard error of the mean. ***P≦0.001 by one-way ANOVA with Sidak's multiple comparison test. [Figure 15-2] See description of Figure 15-1. [Figure 15-3] See description of Figure 15-1. [Figure 15-4] See description of Figure 15-1. [Figure 15-5] See description of Figure 15-1. DETAILED DESCRIPTION OF THE INVENTION

[0017] Detailed Description This document provides methods and materials for treating T cell cancer. In some cases, this document provides bispecific molecules that can be used to treat T cell cancer. For example, this document provides bispecific molecules comprising at least two antigen-binding domains, where a first antigen-binding domain (e.g., a first scFv) can bind to a TRBV polypeptide and a second antigen-binding domain (e.g., a second scFv) can bind to a T cell co-receptor polypeptide, which can be used to treat a mammal (e.g., a human) with T cell cancer. This document also provides methods for treating T cell cancer. For example, one or more bispecific molecules provided herein (e.g., a composition containing one or more bispecific molecules provided herein) can be administered to a mammal with T cell cancer to treat the mammal. In some cases, a bispecific molecule provided herein (e.g., a bispecific molecule comprising a first antigen-binding domain capable of binding to a TRBV polypeptide and a second antigen-binding domain capable of binding to a T cell co-receptor polypeptide) can activate T cells in a mammal to target (e.g., target and destroy) T cells that express a TRBV polypeptide that can be targeted by the bispecific molecule. For example, a T cell that expresses a T cell co-receptor polypeptide that can be targeted by a bispecific molecule provided herein can be activated to target (e.g., target and destroy) T cells (e.g., cancerous T cells) that express a TRBV polypeptide that can be targeted by the bispecific molecule.

[0018] Any suitable mammal (e.g., a mammal having a T-cell cancer) can be treated as described herein. For example, humans, non-human primates (e.g., monkeys), horses, bovine species, porcine species, dogs, cats, mice, and rats can be treated as described herein. In some cases, a human having a T-cell cancer can be administered one or more bispecific molecules provided herein (e.g., a bispecific molecule comprising a first antigen-binding domain capable of binding to a TRBV polypeptide and a second antigen-binding domain capable of binding to a T-cell co-receptor polypeptide).

[0019] The materials and methods described herein can be used to treat mammals (e.g., humans) with any type of T cell cancer. In some cases, the T cell cancer treated as described herein can include one or more solid tumors. In some cases, the T cell cancer treated as described herein can be a hematological cancer. In some cases, the T cell cancer treated as described herein can be a primary cancer. In some cases, the T cell cancer treated as described herein can be a metastatic cancer. In some cases, the T cell cancer treated as described herein can be a refractory cancer. In some cases, the T cell cancer treated as described herein can be a non-Hodgkin's lymphoma. In some cases, the T cell cancer treated as described herein can be a Hodgkin's lymphoma. Examples of T cell cancers that can be treated as described herein include, but are not limited to, ALL, PTCL, AITL, T-PLL, ATLL, EATL, MEITL, FTCL, nodal PTCL, CTCL, ALCL, T-LGL, NKTL, and hepatosplenic T cell lymphoma.

[0020] In some cases, the materials and methods provided herein can be used to reduce or eliminate the number of cancer cells present in a mammal (e.g., a human) with T-cell cancer. For example, one or more bispecific molecules provided herein (e.g., a bispecific molecule comprising a first antigen-binding domain capable of binding to a TRBV polypeptide and a second antigen-binding domain capable of binding to a T-cell co-receptor polypeptide) can be administered to a mammal in need thereof (e.g., a mammal with T-cell cancer) to reduce or eliminate the number of cancer cells present in the mammal. For example, the materials and methods described herein can be used to reduce the number of cancer cells present in a mammal with cancer by, for example, 10, 20, 30, 40, 50, 60, 70, 80, 90, 95, or more percent. For example, the materials and methods described herein can be used to reduce the size (e.g., volume) of one or more tumors present in a mammal with cancer by, for example, 10, 20, 30, 40, 50, 60, 70, 80, 90, 95, or more percent. In some cases, the number of cancer cells present in the mammal undergoing treatment can be monitored. Any suitable method can be used to determine whether the number of cancer cells present in the mammal has been reduced, for example, imaging techniques can be used to assess the number of cancer cells present in the mammal.

[0021] In some cases, the materials and methods provided herein can be used to improve the survival of a mammal (e.g., a human) with a T-cell cancer. For example, one or more bispecific molecules provided herein (e.g., a bispecific molecule comprising a first antigen-binding domain capable of binding to a TRBV polypeptide and a second antigen-binding domain capable of binding to a T-cell co-receptor polypeptide) can be administered to a mammal in need thereof (e.g., a mammal with a T-cell cancer) to improve the survival of the mammal. For example, the materials and methods described herein can be used to improve the survival of a mammal with cancer by, for example, 10, 20, 30, 40, 50, 60, 70, 80, 90, 95, or more percent. For example, the materials and methods described herein can be used to improve the survival of a mammal with cancer by, for example, at least 6 months (e.g., about 6 months, about 8 months, about 10 months, about 1 year, about 1.5 years, about 2 years, about 2.5 years, about 3 years, about 4 years, about 5 years, or more).

[0022] In some cases, when one or more bispecific molecules provided herein (e.g., a bispecific molecule comprising a first antigen-binding domain capable of binding to a TRBV polypeptide and a second antigen-binding domain capable of binding to a T cell co-receptor polypeptide) are administered to a mammal in need thereof (e.g., a mammal having a T cell cancer), a majority of normal T cells within the mammal can be preserved. For example, using the materials and methods described herein, a mammal having a T cell cancer as described herein can be treated while preserving, for example, 50, 60, 70, 80, 90, 95, or more percent of normal (e.g., non-cancerous) T cells within the mammal. In some cases, when a mammal is administered one or more bispecific molecules provided herein, about 75 percent to about 100 percent (e.g., about 75 percent to about 99 percent, about 75 percent to about 95 percent, about 75 percent to about 93 percent, about 75 percent to about 90 percent, about 75 percent to about 85 percent, about 80 percent to about 100 percent, about 85 percent to about 100 percent, about 90 percent to about 100 percent, or about 95 percent to about 100 percent) of normal (e.g., non-cancerous) T cells in the mammal can be preserved.

[0023] In some cases, the methods described herein can also include identifying a mammal as having T cell cancer. Examples of methods for identifying a mammal as having T cell cancer include, but are not limited to, physical examination, clinical tests (e.g., blood and / or urine), biopsy, imaging tests (e.g., X-ray, PET / CT, MRI, and / or ultrasound), nuclear medicine tests (e.g., bone scan), endoscopy, and / or genetic testing. Once identified as having T cell cancer, the mammal can be administered or instructed to administer one or more bispecific molecules provided herein (e.g., bispecific molecules comprising a first antigen-binding domain capable of binding to a TRBV polypeptide and a second antigen-binding domain capable of binding to a T cell co-receptor polypeptide).

[0024] Any suitable bispecific molecule can be administered to a mammal (e.g., a human) as described herein. In some cases, a bispecific molecule can comprise at least two (e.g., two, three, or four) antigen-binding domains, where a first antigen-binding domain (e.g., a first scFv) can bind to a TRBV polypeptide and a second antigen-binding domain (e.g., a second scFv) can bind to a T cell co-receptor polypeptide. In some cases, a bispecific molecule provided herein can comprise a first antigen-binding domain capable of binding to a TRBV polypeptide and a second antigen-binding domain capable of binding to a T cell co-receptor polypeptide.

[0025] The first antigen-binding domain in the bispecific molecules provided herein (e.g., bispecific molecules comprising a first antigen-binding domain capable of binding to a TRBV polypeptide and a second antigen-binding domain capable of binding to a T cell co-receptor polypeptide) can be any suitable type of antigen-binding domain. In some cases, the first antigen-binding domain that can be used in the bispecific molecules provided herein can comprise a variable region of an immunoglobulin light chain (VL) and a variable region of an immunoglobulin heavy chain (VH). For example, the first antigen-binding domain that can be used in the bispecific molecules provided herein can comprise a first complementarity-determining region (CDR) (VH) from an immunoglobulin light chain. L CDR1), the second CDR from the immunoglobulin light chain (V L CDR2), and the third CDR (V L CDR3), the first CDR from the immunoglobulin heavy chain (V H CDR1), the second CDR from the immunoglobulin heavy chain (V H CDR2), and the third CDR from the immunoglobulin heavy chain (V HCDR2). Examples of antigen-binding domains that can be used as the first antigen-binding domain in the bispecific molecules provided herein include, but are not limited to, single-chain variable fragments (scFv), antigen-binding fragments (Fab), F(ab')2 fragments, and biologically active fragments thereof (e.g., fragments that retain the ability to bind to a target molecule, such as a TRBV polypeptide). In some cases, an antigen-binding domain that can be used as the first antigen-binding domain in the bispecific molecules provided herein can be an scFv.

[0026] The first antigen-binding domain in the bispecific molecules provided herein (e.g., bispecific molecules comprising a first antigen-binding domain capable of binding to a TRBV polypeptide and a second antigen-binding domain capable of binding to a T cell co-receptor polypeptide) can bind to any suitable TRBV. Examples of TRBV that can be targeted by the first antigen-binding domain in the bispecific molecules provided herein include, but are not limited to, TRBV2 polypeptide, TRBV3-1 polypeptide, TRBV4-1 polypeptide, TRBV4-2 polypeptide, TRBV4-3 polypeptide, TRBV5-1 polypeptide, TRBV5-4 polypeptide, TRBV5-5 polypeptide, TRBV5-6 polypeptide, TRBV5-8 polypeptide, TRBV6-1 polypeptide, TRBV6-2 polypeptide, TRBV6-3 polypeptide, TRBV6-4 polypeptide, TRBV6-5 polypeptide, TRBV6-6 polypeptide, TRBV6-8 polypeptide, TRBV6-9 polypeptide, TRBV7-2 polypeptide, TRBV7-3 polypeptide, TRBV7-4 polypeptide, These include TRBV7-6 polypeptides, TRBV7-7 polypeptides, TRBV7-8 polypeptides, TRBV7-9 polypeptides, TRBV9 polypeptides, TRBV10-1 polypeptides, TRBV10-2 polypeptides, TRBV10-3 polypeptides, TRBV11-1 polypeptides, TRBV11-2 polypeptides, TRBV11-3 polypeptides, TRBV12-2 polypeptides, TRBV12-3 polypeptides, TRBV12-4 polypeptides, TRBV12-5 polypeptides, TRBV13 polypeptides, TRBV14 polypeptides, TRBV15 polypeptides, TRBV16 polypeptides, TRBV18 polypeptides, TRBV19 polypeptides, TRBV20-1 polypeptides, TRBV24-1 polypeptides, TRBV25-1 polypeptides, TRBV27 TRBV28 polypeptides, TRBV29-1 polypeptides, and TRBV30 polypeptides. In some cases, the first antigen-binding domain that binds to a TRBV is specific for that TRBV.For example, the first antigen-binding domain that binds to TRBV has a dissociation constant (K) of about 2 nM to about 30 nM (e.g., about 2 nM to about 25 nM, about 2 nM to about 20 nM, about 2 nM to about 15 nM, about 2 nM to about 10 nM, about 2 nM to about 5 nM, about 5 nM to about 30 nM, about 10 nM to about 30 nM, about 15 nM to about 30 nM, about 20 nM to about 30 nM, about 25 nM to about 30 nM, about 2.6 nM to about 25.2 nM, about 5 nM to about 20 nM, about 10 nM to about 15 nM, about 5 nM to about 10 nM, about 15 nM to about 20 nM, or about 20 nM to about 25 nM). D ) with an affinity having a specific binding affinity to a TRBV. In some cases, the first antigen-binding domain that specifically binds to a TRBV does not bind (or does not substantially bind) to a different TRBV. In some cases, the first antigen-binding domain in the bispecific molecules provided herein can be as described elsewhere (see, e.g., Wang et al., Nat. Genet., 47, 1426-1434 (2015); and de Masson et al., Sci. Transl. Med., 10, (2018)).

[0027] In some cases, the first antigen-binding domain that can be used in the bispecific molecules provided herein can bind to a TRBV5-5 polypeptide. For example, an antigen-binding domain that can bind to a TRBV5-5 polypeptide can include each of the CDRs shown below: TIFF2023551535000001.tif53161

[0028] In some cases, the antigen-binding domain capable of binding to a TRBV5-5 polypeptide comprises a V polypeptide comprising the amino acid sequence set forth in SEQ ID NO:1. L CDR1, V comprising the amino acid sequence shown in SEQ ID NO:2 L CDR2, and V comprising the amino acid sequence shown in SEQ ID NO:3 LFor example, an antigen-binding domain capable of binding to a TRBV5-5 polypeptide may comprise a light chain having a CDR3. For example, an antigen-binding domain capable of binding to a TRBV5-5 polypeptide may comprise a light chain having the amino acid sequence set forth in SEQ ID NO:7. For example, an antigen-binding domain capable of binding to a TRBV5-5 polypeptide may comprise a light chain having the amino acid sequence set forth in SEQ ID NO:38. In some cases, an antigen-binding domain capable of binding to a TRBV5-5 polypeptide may comprise a light chain having the amino acid sequence set forth in SEQ ID NO:4. H CDR1, V comprising the amino acid sequence set forth in SEQ ID NO:5 H CDR2, and V comprising the amino acid sequence shown in SEQ ID NO:6 H For example, an antigen-binding domain capable of binding to a TRBV5-5 polypeptide may comprise a heavy chain having a CDR3. For example, an antigen-binding domain capable of binding to a TRBV5-5 polypeptide may comprise a heavy chain having the amino acid sequence set forth in SEQ ID NO:8. For example, an antigen-binding domain capable of binding to a TRBV5-5 polypeptide may comprise a heavy chain having the amino acid sequence set forth in SEQ ID NO:39. In some cases, an antigen-binding domain capable of binding to a TRBV5-5 polypeptide may comprise a V having the amino acid sequence set forth in SEQ ID NO:1. L CDR1, V comprising the amino acid sequence shown in SEQ ID NO:2 L CDR2, and V comprising the amino acid sequence shown in SEQ ID NO:3 L and a light chain having a CDR3 and a V comprising the amino acid sequence set forth in SEQ ID NO:4. H CDR1, V comprising the amino acid sequence set forth in SEQ ID NO:5 H CDR2, and V comprising the amino acid sequence shown in SEQ ID NO:6 H It may comprise a heavy chain having a CDR3. For example, an antigen-binding domain capable of binding to a TRBV5-5 polypeptide may comprise a light chain comprising the amino acid sequence shown in SEQ ID NO: 7 and a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 8. For example, an antigen-binding domain capable of binding to a TRBV5-5 polypeptide may comprise a light chain comprising the amino acid sequence shown in SEQ ID NO: 38 and a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 39.

[0029] In some cases, the first antigen-binding domain that can be used in the bispecific molecules provided herein can bind to a TRBV12 polypeptide. For example, an antigen-binding domain that can bind to a TRBV12 polypeptide can include each of the CDRs shown below: TIFF2023551535000002.tif53161

[0030] In some cases, the antigen-binding domain capable of binding to a TRBV12 polypeptide comprises a V polypeptide comprising the amino acid sequence set forth in SEQ ID NO:9. L CDR1, V comprising the amino acid sequence shown in SEQ ID NO:10 L CDR2, and V comprising the amino acid sequence shown in SEQ ID NO:11 L For example, an antigen-binding domain capable of binding to a TRBV12 polypeptide may comprise a light chain having a CDR3. For example, an antigen-binding domain capable of binding to a TRBV12 polypeptide may comprise a light chain having the amino acid sequence shown in SEQ ID NO: 15. For example, an antigen-binding domain capable of binding to a TRBV12 polypeptide may comprise a light chain having the amino acid sequence shown in SEQ ID NO: 40. In some cases, an antigen-binding domain capable of binding to a TRBV12 polypeptide may comprise a light chain having the amino acid sequence shown in SEQ ID NO: 12. H CDR1, V comprising the amino acid sequence set forth in SEQ ID NO:13 H CDR2, and V comprising the amino acid sequence set forth in SEQ ID NO: 14 H For example, an antigen-binding domain capable of binding to a TRBV12 polypeptide may comprise a heavy chain having a CDR3. For example, an antigen-binding domain capable of binding to a TRBV12 polypeptide may comprise a heavy chain having the amino acid sequence set forth in SEQ ID NO: 16. For example, an antigen-binding domain capable of binding to a TRBV12 polypeptide may comprise a heavy chain having the amino acid sequence set forth in SEQ ID NO: 41. In some cases, an antigen-binding domain capable of binding to a TRBV12 polypeptide may comprise a V having the amino acid sequence set forth in SEQ ID NO: 9. L CDR1, V comprising the amino acid sequence shown in SEQ ID NO:10 LCDR2, and V comprising the amino acid sequence shown in SEQ ID NO:11 L and a light chain having a CDR3 and a V comprising the amino acid sequence set forth in SEQ ID NO: 12. H CDR1, V comprising the amino acid sequence set forth in SEQ ID NO:13 H CDR2, and V comprising the amino acid sequence set forth in SEQ ID NO: 14 H For example, an antigen-binding domain capable of binding to a TRBV12 polypeptide may comprise a light chain comprising the amino acid sequence set forth in SEQ ID NO: 15 and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 16. For example, an antigen-binding domain capable of binding to a TRBV5-5 polypeptide may comprise a light chain comprising the amino acid sequence set forth in SEQ ID NO: 40 and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 41.

[0031] In some cases, the first antigen-binding domain in the bispecific molecules provided herein (e.g., bispecific molecules comprising a first antigen-binding domain capable of binding to a TRBV polypeptide and a second antigen-binding domain capable of binding to a T cell co-receptor polypeptide) can be as described elsewhere (e.g., Beta Mark TCR Vbeta Repertoire Kit, 25 Tests, RUO, Package insert. Beckman Coulter Life Sciences, Technical Document (2009); and U.S. Patent No. 5,861,155, see, e.g., Figure 1).

[0032] The second antigen-binding domain in the bispecific molecules provided herein (e.g., bispecific molecules comprising a first antigen-binding domain capable of binding to a TRBV polypeptide and a second antigen-binding domain capable of binding to a T cell co-receptor polypeptide) can be any suitable type of antigen-binding domain. In some cases, the second antigen-binding domain that can be used in the bispecific molecules provided herein can comprise a variable region of an immunoglobulin light chain (VL) and a variable region of an immunoglobulin heavy chain (VH). For example, the second antigen-binding domain that can be used in the bispecific molecules provided herein can comprise a first complementarity-determining region (CDR) (VH) from an immunoglobulin light chain. L CDR1), the second CDR from the immunoglobulin light chain (V L CDR2), and the third CDR (V L CDR3), the first CDR from the immunoglobulin heavy chain (V H CDR1), the second CDR from the immunoglobulin heavy chain (V H CDR2), and the third CDR from the immunoglobulin heavy chain (V H CDR2). Examples of antigen-binding domains that can be used as the second antigen-binding domain in the bispecific molecules provided herein include, but are not limited to, scFv, Fab, F(ab')2 fragments, and biologically active fragments thereof (e.g., fragments that retain the ability to bind to a target molecule such as a T-cell co-receptor polypeptide). In some cases, an antigen-binding domain that can be used as the second antigen-binding domain in the bispecific molecules provided herein can be an scFv.

[0033] The second antigen-binding domain in the bispecific molecules provided herein (e.g., bispecific molecules comprising a first antigen-binding domain capable of binding to a TRBV polypeptide and a second antigen-binding domain capable of binding to a T cell co-receptor polypeptide) can bind to any suitable T cell co-receptor polypeptide. Examples of T cell co-receptor polypeptides that can be targeted by the second antigen-binding domain in the bispecific molecules provided herein include, but are not limited to, CD3 polypeptides and T cell receptor polypeptides.

[0034] In some cases, a second antigen-binding domain that can be used in the bispecific molecules provided herein can bind to a CD3 polypeptide. For example, an antigen-binding domain that can bind to a CD3 polypeptide can comprise one of each of the CDRs shown below: TIFF2023551535000003.tif180161

[0035] In some cases, the antigen-binding domain capable of binding to a CD3 polypeptide comprises a V domain comprising the amino acid sequence set forth in SEQ ID NO:17. L CDR1, V comprising the amino acid sequence set forth in SEQ ID NO:18 L CDR2, and V comprising the amino acid sequence shown in SEQ ID NO: 19 L For example, an antigen-binding domain capable of binding to a CD3 polypeptide may comprise a light chain comprising the amino acid sequence set forth in SEQ ID NO: 23. For example, an antigen-binding domain capable of binding to a CD3 polypeptide may comprise a light chain comprising the amino acid sequence set forth in SEQ ID NO: 42.

[0036] In some cases, the antigen binding domain capable of binding to a CD3 polypeptide comprises a V domain comprising the amino acid sequence set forth in SEQ ID NO:44. L CDR1, V comprising the amino acid sequence set forth in SEQ ID NO:48 L CDR2, and V comprising the amino acid sequence set forth in SEQ ID NO:51 L For example, an antigen-binding domain capable of binding to a CD3 polypeptide may comprise a light chain comprising the amino acid sequence set forth in SEQ ID NO:61.

[0037] In some cases, the antigen binding domain capable of binding to a CD3 polypeptide comprises a V L CDR1, V comprising the amino acid sequence set forth in SEQ ID NO:49 LCDR2, and V comprising the amino acid sequence set forth in SEQ ID NO:52 L For example, an antigen-binding domain capable of binding to a CD3 polypeptide may comprise a light chain comprising the amino acid sequence set forth in SEQ ID NO:63.

[0038] In some cases, the antigen binding domain capable of binding to a CD3 polypeptide comprises a V domain comprising the amino acid sequence set forth in SEQ ID NO:46. L CDR1, V comprising the amino acid sequence shown in SEQ ID NO:50 L CDR2, and V comprising the amino acid sequence set forth in SEQ ID NO:53 L For example, an antigen-binding domain capable of binding to a CD3 polypeptide may comprise a light chain comprising the amino acid sequence set forth in SEQ ID NO:65.

[0039] In some cases, the antigen-binding domain capable of binding to a CD3 polypeptide comprises a V domain comprising the amino acid sequence set forth in SEQ ID NO:47. L CDR1, V comprising the amino acid sequence set forth in SEQ ID NO:48 L CDR2, and V comprising the amino acid sequence set forth in SEQ ID NO:51 L For example, an antigen-binding domain capable of binding to a CD3 polypeptide may comprise a light chain comprising the amino acid sequence set forth in SEQ ID NO:67.

[0040] In some cases, the antigen-binding domain capable of binding to a CD3 polypeptide comprises a V domain comprising the amino acid sequence set forth in SEQ ID NO:20. H CDR1, V comprising the amino acid sequence shown in SEQ ID NO:21 H CDR2, and V comprising the amino acid sequence shown in SEQ ID NO:22 HFor example, an antigen-binding domain capable of binding to a CD3 polypeptide may comprise a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 24. For example, an antigen-binding domain capable of binding to a CD3 polypeptide may comprise a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 43.

[0041] In some cases, the antigen binding domain capable of binding to a CD3 polypeptide comprises a V domain comprising the amino acid sequence set forth in SEQ ID NO:54. H CDR1, V comprising the amino acid sequence set forth in SEQ ID NO:56 H CDR2, and V comprising the amino acid sequence set forth in SEQ ID NO:59 H For example, an antigen-binding domain capable of binding to a CD3 polypeptide may comprise a heavy chain comprising the amino acid sequence shown in SEQ ID NO:62.

[0042] In some cases, the antigen binding domain capable of binding to a CD3 polypeptide comprises a V domain comprising the amino acid sequence set forth in SEQ ID NO:54. H CDR1, V comprising the amino acid sequence set forth in SEQ ID NO:56 H CDR2, and V comprising the amino acid sequence set forth in SEQ ID NO:59 H For example, an antigen-binding domain capable of binding to a CD3 polypeptide may comprise a heavy chain comprising the amino acid sequence shown in SEQ ID NO:64.

[0043] In some cases, the antigen binding domain capable of binding to a CD3 polypeptide comprises a V H CDR1, V comprising the amino acid sequence set forth in SEQ ID NO:57 H CDR2, and V comprising the amino acid sequence shown in SEQ ID NO:60 H For example, an antigen-binding domain capable of binding to a CD3 polypeptide may comprise a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:66.

[0044] In some cases, the antigen binding domain capable of binding to a CD3 polypeptide comprises a V domain comprising the amino acid sequence set forth in SEQ ID NO:54. H CDR1, V comprising the amino acid sequence set forth in SEQ ID NO:58 H CDR2, and V comprising the amino acid sequence set forth in SEQ ID NO:59 H For example, an antigen-binding domain capable of binding to a CD3 polypeptide may comprise a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:68.

[0045] In some cases, the antigen-binding domain capable of binding to a CD3 polypeptide comprises a V domain comprising the amino acid sequence set forth in SEQ ID NO:17. L CDR1, V comprising the amino acid sequence set forth in SEQ ID NO:18 L CDR2, and V comprising the amino acid sequence shown in SEQ ID NO: 19 L and a light chain having a CDR3 and comprising the amino acid sequence set forth in SEQ ID NO: 20. H CDR1, V comprising the amino acid sequence shown in SEQ ID NO:21 H CDR2, and V comprising the amino acid sequence shown in SEQ ID NO:22 H For example, an antigen-binding domain capable of binding to a CD3 polypeptide may comprise a light chain comprising the amino acid sequence set forth in SEQ ID NO:23, and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:24. For example, an antigen-binding domain capable of binding to a CD3 polypeptide may comprise a light chain comprising the amino acid sequence set forth in SEQ ID NO:42, and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:43.

[0046] In some cases, the antigen binding domain capable of binding to a CD3 polypeptide comprises a V domain comprising the amino acid sequence set forth in SEQ ID NO:44. L CDR1, V comprising the amino acid sequence set forth in SEQ ID NO:48L CDR2, and V comprising the amino acid sequence set forth in SEQ ID NO:51 L and a light chain having a CDR3 and comprising the amino acid sequence set forth in SEQ ID NO: 54. H CDR1, V comprising the amino acid sequence set forth in SEQ ID NO:56 H CDR2, and V comprising the amino acid sequence set forth in SEQ ID NO:59 H For example, an antigen-binding domain capable of binding to a CD3 polypeptide may comprise a light chain comprising the amino acid sequence set forth in SEQ ID NO:61 and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:62.

[0047] In some cases, the antigen binding domain capable of binding to a CD3 polypeptide comprises a V L CDR1, V comprising the amino acid sequence set forth in SEQ ID NO:49 L CDR2, and V comprising the amino acid sequence set forth in SEQ ID NO:52 L and a light chain having a CDR3 and comprising the amino acid sequence set forth in SEQ ID NO: 54. H CDR1, V comprising the amino acid sequence set forth in SEQ ID NO:56 H CDR2, and V comprising the amino acid sequence set forth in SEQ ID NO:59 H For example, an antigen-binding domain capable of binding to a CD3 polypeptide may comprise a light chain comprising the amino acid sequence set forth in SEQ ID NO:63 and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:64.

[0048] In some cases, the antigen binding domain capable of binding to a CD3 polypeptide comprises a V domain comprising the amino acid sequence set forth in SEQ ID NO:46. L CDR1, V comprising the amino acid sequence shown in SEQ ID NO:50 L CDR2, and V comprising the amino acid sequence set forth in SEQ ID NO:53 Land a light chain having a CDR3 and comprising the amino acid sequence set forth in SEQ ID NO: 55. H CDR1, V comprising the amino acid sequence set forth in SEQ ID NO:57 H CDR2, and V comprising the amino acid sequence shown in SEQ ID NO:60 H For example, an antigen-binding domain capable of binding to a CD3 polypeptide may comprise a light chain comprising the amino acid sequence set forth in SEQ ID NO:65 and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:66.

[0049] In some cases, the antigen-binding domain capable of binding to a CD3 polypeptide comprises a V domain comprising the amino acid sequence set forth in SEQ ID NO:47. L CDR1, V comprising the amino acid sequence set forth in SEQ ID NO:48 L CDR2, and V comprising the amino acid sequence set forth in SEQ ID NO:51 L and a light chain having a CDR3 and comprising the amino acid sequence set forth in SEQ ID NO: 54. H CDR1, V comprising the amino acid sequence set forth in SEQ ID NO:58 H CDR2, and V comprising the amino acid sequence set forth in SEQ ID NO:59 H For example, an antigen-binding domain capable of binding to a CD3 polypeptide may comprise a light chain comprising the amino acid sequence set forth in SEQ ID NO:67 and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:68.

[0050] In some cases, the second antigen-binding domain in the bispecific molecules provided herein (e.g., bispecific molecules comprising a first antigen-binding domain capable of binding to a TRBV polypeptide and a second antigen-binding domain capable of binding to a T cell co-receptor polypeptide) can be as described elsewhere (see, e.g., Zhu et al., Journal of Immunology, 155:1903-1910 (1995); and Junttila et al., Cancer Research, 74:5561-5571 (2014)).

[0051] In some cases, the first and second antigen-binding domains in the bispecific molecules provided herein (e.g., bispecific molecules comprising a first antigen-binding domain capable of binding to a TRBV polypeptide and a second antigen-binding domain capable of binding to a T cell co-receptor polypeptide) can be linked via a linker (e.g., a polypeptide linker). The linker can comprise any suitable number of amino acids. For example, the linker can comprise about 5 amino acids to about 20 amino acids (e.g., about 5 amino acids to about 18 amino acids, about 5 amino acids to about 15 amino acids, about 5 amino acids to about 12 amino acids, about 5 amino acids to about 10 amino acids, about 5 amino acids to about 8 amino acids, about 7 amino acids to about 20 amino acids, about 10 amino acids to about 20 amino acids, about 12 amino acids to about 20 amino acids, about 16 amino acids to about 20 amino acids, about 8 amino acids to about 16 amino acids, about 10 amino acids to about 12 amino acids, about 8 amino acids to about 12 amino acids, about 10 amino acids to about 15 amino acids, or about 12 amino acids to about 16 amino acids). In some cases, the linker can alter the mobility of the bispecific molecule. In some cases, the linker can alter the solubility of the bispecific molecule. The linker can comprise any suitable amino acid. In some cases, the linker can be a glycine-rich linker. In some cases, the linker may be a serine- and / or threonine-rich linker. The linker can link the first and second antigen-binding domains in the bispecific molecules provided herein in any order. For example, the linker can connect the N-terminus of the first antigen-binding domain in the bispecific molecules provided herein to the C-terminus of the second antigen-binding domain in the bispecific molecules provided herein, or vice versa. Examples of linkers that can be used to connect the first and second antigen-binding domains in the bispecific molecules provided herein include, but are not limited to, a GGGGS linker (SEQ ID NO:25), a (GGGGS)3 linker (SEQ ID NO:26), and Includes TIFF2023551535000004.tif4128.

[0052] In some cases, one or more bispecific molecules provided herein (e.g., a bispecific molecule comprising a first antigen-binding domain capable of binding to a TRBV polypeptide and a second antigen-binding domain capable of binding to a T cell co-receptor polypeptide) can be formulated into a composition (e.g., a pharmaceutical composition) for administration to a mammal (e.g., a human). For example, one or more bispecific molecules provided herein can be formulated into a pharmaceutically acceptable composition for administration to a mammal (e.g., a human) with T cell cancer. In some cases, one or more bispecific molecules provided herein can be formulated together with one or more pharmaceutically acceptable carriers (additives), excipients, and / or diluents.Examples of pharmaceutically acceptable carriers, excipients, and diluents that can be used in the compositions described herein include, but are not limited to, sucrose, lactose, starch (e.g., starch glycolate), cellulose, cellulose derivatives (e.g., modified cellulose, e.g., microcrystalline cellulose and cellulose ethers such as hydroxypropyl cellulose (HPC) and the cellulose ether hydroxypropylmethylcellulose (HPMC)), xylitol, sorbitol, mannitol, gelatin, polymers (e.g., polyvinylpyrrolidone (PVP), polyethylene glycol (PEG), cross-linked polyvinylpyrrolidone (crospovidone), carboxymethylcellulose, polyethylene-polyoxypropylene-block copolymers, and cross-linked sodium carboxymethylcellulose (croscal), and the like. Ingredients include: cellulose (sodium stearate), titanium dioxide, azo dyes, silica gel, fumed silica, talc, magnesium carbonate, vegetable stearin, magnesium stearate, aluminum stearate, stearic acid, antioxidants (e.g., vitamin A, vitamin E, vitamin C, retinyl palmitate, and selenium), citric acid, sodium citrate, parabens (e.g., methylparaben and propylparaben), petrolatum, dimethyl sulfoxide, mineral oil, serum proteins (e.g., human serum albumin), glycine, sorbic acid, potassium sorbate, water, salts or electrolytes (e.g., saline, protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, and zinc salts), colloidal silica, magnesium trisilicate, polyacrylate, wax, wool fat, and lecithin.

[0053] Compositions (e.g., pharmaceutical compositions) containing one or more bispecific molecules provided herein (e.g., bispecific molecules comprising a first antigen-binding domain capable of binding to a TRBV polypeptide and a second antigen-binding domain capable of binding to a T cell co-receptor polypeptide) can be formulated into any suitable dosage form. Exemplary dosage forms include, but are not limited to, solid or liquid forms, including pills, capsules, tablets, gels, liquids, suspensions, solutions (e.g., sterile solutions), sustained-release formulations, and delayed-release formulations.

[0054] Compositions (e.g., pharmaceutical compositions) containing one or more bispecific molecules provided herein (e.g., bispecific molecules comprising a first antigen-binding domain capable of binding to a TRBV polypeptide and a second antigen-binding domain capable of binding to a T cell co-receptor polypeptide) can be designed for oral or parenteral (e.g., topical, subcutaneous, intravenous, intraperitoneal, intrathecal, and intraventricular) administration. When administered orally, the compositions can be in the form of a pill, tablet, or capsule. Compositions suitable for parenteral administration include aqueous and non-aqueous sterile injectable solutions which may contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations can be presented in unit-dose or multi-dose containers, e.g., sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of a sterile liquid carrier, e.g., water for injection, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.

[0055] Compositions (e.g., pharmaceutical compositions) containing one or more bispecific molecules provided herein (e.g., bispecific molecules comprising a first antigen-binding domain capable of binding to a TRBV polypeptide and a second antigen-binding domain capable of binding to a T cell co-receptor polypeptide) can be administered locally or systemically. For example, compositions containing one or more bispecific molecules provided herein can be administered systemically to a mammal (e.g., a human) by intravenous injection. For example, compositions containing one or more bispecific molecules provided herein can be administered systemically to a mammal (e.g., a human) by subcutaneous injection.

[0056] An effective amount (e.g., an effective dose) of one or more bispecific molecules provided herein (e.g., a bispecific molecule comprising a first antigen-binding domain capable of binding to a TRBV polypeptide and a second antigen-binding domain capable of binding to a T-cell co-receptor polypeptide) may vary depending on the severity of the T-cell cancer, the route of administration, the age and general health of the subject, the use of excipients, the possibility of concurrent use with other therapeutic treatments, such as the use of other agents, and / or the judgment of the treating physician.

[0057] An effective amount of a composition (e.g., a pharmaceutical composition) containing one or more bispecific molecules provided herein (e.g., a bispecific molecule comprising a first antigen-binding domain capable of binding to a TRBV polypeptide and a second antigen-binding domain capable of binding to a T cell co-receptor polypeptide) can be any amount capable of treating a mammal (e.g., a human) with a T cell cancer without causing significant toxicity to the mammal. An effective amount of one or more bispecific molecules provided herein can be any appropriate amount. The effective amount can remain constant or can be adjusted as a sliding scale or variable dose depending on the mammal's response to treatment. Various factors can affect the actual effective amount used for a particular application. For example, the frequency of administration, the duration of treatment, the use of multiple therapeutic agents, the route of administration, and the severity of the condition (e.g., T cell cancer) may require an increase or decrease in the actual effective amount administered.

[0058] The frequency of administration of a composition (e.g., a pharmaceutical composition) containing one or more bispecific molecules provided herein (e.g., a bispecific molecule comprising a first antigen-binding domain capable of binding to a TRBV polypeptide and a second antigen-binding domain capable of binding to a T cell co-receptor polypeptide) can be any frequency capable of treating a mammal (e.g., a human) with T cell cancer without causing significant toxicity to the mammal. For example, the frequency of administration can be once daily, once weekly, once every two weeks, or once every four weeks. In some cases, administration can include continuous infusion of a composition containing one or more bispecific molecules provided herein. The frequency of administration can remain constant or can vary over the duration of treatment. A treatment course using a composition containing one or more bispecific molecules provided herein can include rest periods. As with the effective amount, various factors can affect the actual frequency of administration used for a particular application. For example, the effective amount, the duration of treatment, the use of multiple therapeutic agents, the route of administration, and the severity of the condition (e.g., T cell cancer) may require an increase or decrease in the frequency of administration.

[0059] The effective duration for administering a composition (e.g., a pharmaceutical composition) containing one or more bispecific molecules provided herein (e.g., a bispecific molecule comprising a first antigen-binding domain capable of binding to a TRBV polypeptide and a second antigen-binding domain capable of binding to a T cell co-receptor polypeptide) can be any duration that treats a mammal (e.g., a human) with T cell cancer without causing significant toxicity to the mammal. For example, the effective duration can vary from several days to several weeks, months, or years. In some cases, the effective duration for treating a mammal can range in duration from about one month to about 10 years. Multiple factors can affect the actual effective duration used for a particular treatment. For example, the effective duration can vary with the frequency of administration, the effective amount, the use of multiple therapeutic agents, the route of administration, and the severity of the condition (e.g., T cell cancer) being treated.

[0060] In some cases, one or more bispecific molecules provided herein (e.g., a bispecific molecule comprising a first antigen-binding domain capable of binding to a TRBV polypeptide and a second antigen-binding domain capable of binding to a T-cell co-receptor polypeptide) can be used as a single active agent to treat a mammal (e.g., a human) with a T-cell cancer.

[0061] In some cases, the methods and materials described herein may include one or more (e.g., one, two, three, four, five, or more) additional therapeutic agents used to treat a mammal (e.g., a human) with a T-cell cancer. For example, a mammal in need thereof (e.g., a mammal with a T-cell cancer) can be administered one or more bispecific molecules provided herein (e.g., a bispecific molecule comprising a first antigen-binding domain capable of binding to a TRBV polypeptide and a second antigen-binding domain capable of binding to a T-cell co-receptor polypeptide) in combination with one or more anti-cancer agents. In some cases, the anti-cancer agent may be an alkylating agent. In some cases, the anti-cancer agent may be a platinum compound. In some cases, the anti-cancer agent may be a taxane. In some cases, the anti-cancer agent may be a luteinizing hormone-releasing hormone (LHRH) agonist. In some cases, the anti-cancer agent may be an anti-estrogen. In some cases, the anti-cancer agent may be an aromatase inhibitor. In some cases, the anti-cancer agent may be an angiogenesis inhibitor. In some cases, the anti-cancer agent may be a poly(ADP)-ribose polymerase (PARP) inhibitor. In some cases, the anti-cancer agent may be a topoisomerase inhibitor. In some cases, the anti-cancer agent may be a corticosteroid. In some cases, the anti-cancer agent may be an antibody. In some cases, the anti-cancer agent may be an antibody-drug conjugate. Examples of anti-cancer drugs include, but are not limited to, busulfan, cisplatin, carboplatin, paclitaxel, docetaxel, nab-paclitaxel, altretamine, capecitabine, cyclophosphamide, etoposide (vp-16), gemcitabine, ifosfamide, irinotecan (cpt-11), melphalan, pemetrexed, topotecan, vinorelbine, goserelin, leuprolide, tamoxifen, letrozole, anastrozole, exemestane, bevacizumab, olaparib, rucaparib, niraparib, cyclophosphamide, doxorubicin (e.g., liposomal doxorubicin), prednisone, prednisolone, dexamethasone, mogamulizumab, brentuximab, and any combination thereof.In some cases, one or more additional therapeutic agents can be administered together with one or more bispecific molecules provided herein (e.g., in a single composition). In some cases, one or more additional therapeutic agents can be administered independently from one or more bispecific molecules provided herein. When one or more additional therapeutic agents are administered independently from one or more bispecific molecules provided herein, one or more bispecific molecules provided herein can be administered first and one or more additional therapeutic agents can be administered second, or vice versa.

[0062] In some cases, the methods and materials described herein may include one or more (e.g., one, two, three, four, five, or more) additional therapies (e.g., therapeutic interventions) effective to treat T cell cancer. For example, one or more bispecific molecules provided herein (e.g., a bispecific molecule comprising a first antigen-binding domain capable of binding to a TRBV polypeptide and a second antigen-binding domain capable of binding to a T cell co-receptor polypeptide) can be administered in combination with one or more therapeutic interventions to a mammal in need thereof (e.g., a mammal having T cell cancer). Examples of therapeutic interventions that can be used as described herein to treat T cell cancer include, but are not limited to, cancer surgery, radiation therapy, chemotherapy, and any combination thereof. In some cases, one or more additional therapies effective to treat T cell cancer can be administered simultaneously with the administration of one or more bispecific molecules provided herein. In some cases, one or more additional therapies effective to treat T cell cancer can be administered before and / or after the administration of one or more bispecific molecules provided herein.

[0063] In some cases, one or more bispecific molecules provided herein (e.g., a bispecific molecule comprising a first antigen-binding domain capable of binding to a TRBV polypeptide and a second antigen-binding domain capable of binding to a T cell co-receptor polypeptide) can be used to treat a mammal with a disease or disorder other than cancer. For example, one or more bispecific molecules provided herein can be administered to a mammal with a disease, disorder, or condition other than a T cell cancer associated with clonal T cell expansion. In some cases, the disease, disorder, or condition other than a T cell cancer associated with clonal T cell expansion can be an autoimmune disease. In some cases, the disease, disorder, or condition other than a T cell cancer associated with clonal T cell expansion can be associated with transplant rejection. Examples of diseases and disorders associated with clonal T cell expansion that can be targeted using one or more bispecific molecules provided herein include, but are not limited to, graft-versus-host disease (GVHD), celiac disease, and multiple sclerosis.

[0064] In some cases, the materials and methods described herein can be used to treat a mammal (e.g., a human) with celiac disease. For example, one or more bispecific molecules provided herein (e.g., a bispecific molecule comprising a first antigen-binding domain capable of binding to a TRBV polypeptide and a second antigen-binding domain capable of binding to a T cell co-receptor polypeptide) can be administered to a mammal (e.g., a human) with celiac disease to treat the mammal. In some cases, a bispecific molecule comprising a first antigen-binding domain capable of binding to a TRBV polypeptide associated with celiac disease and a second antigen-binding domain capable of binding to a T cell co-receptor polypeptide (e.g., a CD3 polypeptide) can be administered to a mammal (e.g., a human) with celiac disease to treat the mammal. In some cases where the bispecific molecules provided herein are used to treat a mammal with celiac disease, the first antigen-binding domain of the bispecific molecule can bind to a TRBV polypeptide selected from the group consisting of TRBV4, TRBV6, TRBV7, TRBV9, TRBV20, and TRBV29, and the second antigen-binding domain can bind to a T cell co-receptor polypeptide (e.g., a CD3 polypeptide). In some cases where the bispecific molecules provided herein are used to treat a mammal with celiac disease, the first antigen-binding domain of the bispecific molecule can bind to a TRBV polypeptide selected from the group consisting of TRBV6-1, TRBV7-2, TRBV9-1, TRBV20-1, and TRBV29-1, and the second antigen-binding domain can bind to a T cell co-receptor polypeptide (e.g., a CD3 polypeptide).

[0065] In some cases, the first antigen-binding domain described herein (e.g., a first antigen-binding domain capable of binding to a TRBV polypeptide) can be included in a chimeric antigen receptor (CAR) that can be present on a T cell (CAR T cell). For example, CAR T cells comprising an antigen-binding domain capable of binding to a TRBV polypeptide can be used to treat a mammal with T cell cancer. In some cases, CAR T cells comprising an antigen-binding domain capable of binding to a TRBV polypeptide provided herein can be administered to a mammal with T cell cancer to treat the mammal. CAR T cells comprising an antigen-binding domain capable of binding to a TRBV polypeptide can be used in any type of CAR T cell therapy. CAR T cell therapies can include those described elsewhere (see, e.g., Ali et al., Blood, 128(13):1688-700 (2016); Sadelain et al., Cancer Discov., 3(4):388-98 (2013); Porter et al., N. Engl. J. Med., 365(8):725-33 (2011); and Maciocia et al., Nat. Med., 23(12):1416-1423 (2017)).

[0066] In some cases, the first antigen-binding domain described herein (e.g., a first antigen-binding domain capable of binding to a TRBV polypeptide) can be included in an antibody-drug conjugate (ADC). For example, an ADC comprising an antigen-binding domain capable of binding to a TRBV polypeptide can be used to treat a mammal with T-cell cancer. In some cases, an ADC comprising an antigen-binding domain capable of binding to a TRBV polypeptide provided herein can be administered to a mammal with T-cell cancer to treat the mammal. An ADC comprising an antigen-binding domain capable of binding to a TRBV polypeptide can include any type of drug. Drugs that can be used in ADCs can include those described elsewhere (see, e.g., Younes et al., Lancet Oncol., 14(13):1348-56 (2013); Hamblett et al., Clin. Cancer. Res., 10(20):7063-70 (2004); and Lewis Phillips et al., Cancer Res., 68(22):9280-90 (2008)).

[0067] The invention is further described in the following examples, which do not limit the scope of the invention described in the claims. [Example]

[0068] Example 1: TCR beta chain directed bispecific antibodies for the treatment of T cell cancers This example describes the generation and evaluation of a TRBC-targeted BsAb and two different TRBV-targeted BsAbs for the treatment of T-cell cancer. The TRBC-targeted BsAb can eradicate both T-cell cancer and the vast majority of healthy human (normal) T cells due to its bidirectional T cell killing. The TRBV-targeted BsAb can deplete cancerous T cells in vitro and in vivo while sparing the majority of normal T cells.

[0069] result BsAb targeting of normal T cells Anti-TRBV5-5 and anti-TRBV12 scFv sequences were used to detect TRBV5-5, respectively. + or TRBV12 + Anti-TRBV5-5 and anti-TRBV12 BsAbs (hereafter referred to as "α-V5" and "α-V12") were generated for selective targeting of T cells (Figure 1B, Figure 7A, and Table 1). + An anti-TRBC1 BsAb (hereafter referred to as "α-C1") for selective targeting of T cells was generated (Fig. 1B and Table 1). Analytical chromatography showed a monomeric BsAb with a purity of >99% (Fig. 7B, C). The thermal stability of α-V12 and α-V5 was assessed using differential scanning fluorimetry. α-V5 exhibited a single melting temperature (T) of 78°C. m ) and α-V12 exhibited two T m These data suggest that for α-V5, both the anti-TRBV5-5 scFv and the anti-CD3 scFv unfold at 78°C, while for α-V12, the anti-TRBV12 scFv unfolds at 59°C and the anti-CD3 scFv unfolds at 77°C. We found that 1.5-2% and 3.5-5% of normal human T cells express TRBV5-5 and TRBV12, respectively (Fig. 1C, D). Approximately 35-45% of human T cells express TRBC1, and the remainder express TRBC2 (Fig. 1C, E). In vitro exposure of T cells from healthy individuals to α-V5 and α-V12 treatment resulted in the unfolding of TRBV5-5 and TRBV12, respectively. + and TRBV12 + Similarly, exposure of T cells from healthy donors to α-C1 resulted in a complete loss of TRBC1 cells (Figures 1C, D and 8A). +This resulted in substantial loss of T cells (Figures 1C, E and 8B). However, there was a significant difference in the loss of non-target T cells mediated by TRBV- and TRBC-specific BsAbs. α-V5 BsAb depleted 14.1% (average) of T cells that did not express TRBV5-5, and α-V12 eradicated 13.3% (average) of T cells that did not express TRBV12 (Figure 1C). In contrast, α-C1 eradicated 80.0% (average) of T cells that did not express TRBC1 (Figure 1C). Consequently, α-C1 resulted in the depletion of most total T cells, while α-V5 or α-V12 preserved the majority of T cells (Figure 1C). To confirm that BsAb-mediated TCR internalization or TCR epitope blocking does not interfere with subsequent antibody-based analysis of different T cell subtypes, target cells (TRBV5) stained with CellTrace Violet were stained with β-lactam IgG. + , TRBV12 + or TRBC1 + T cells). α-V5 and α-V12 exposure was measured using TRBV5 cells stained with CellTrace Violet. + and TRBV12 + α-C1 led to the depletion of TRBC1 cells (Figure 8C). + Cells and TRBC2 + caused a substantial loss of both cells (Fig. 8D, E).

[0070] Table 1. Affinities and sequences of α-TRBV5-5, α-TRBV12, α-TRBC1, α-CD19, and α-CD3 scFv TIFF2023551535000005.tif233131

[0071] Rationale for BsAb targeting of T cells that do not express relevant TRBV or TRBC To examine whether BsAbs result in killing of T cells that do not express the relevant TRBV or TRBC chains, we used TRBC1 +Human T cells were depleted, and then the depleted T cells were exposed to α-C1. After depletion of T cells expressing TRBC1, exposure to α-C1 did not result in statistically significant killing of the remaining T cells (Fig. 8F). Similarly, after depletion of T cells expressing either TRBV5 or TRBV12, exposure to α-V5 or α-V12 did not result in statistically significant killing of the remaining T cells (Fig. 8G). In addition, TRBV5 + or TRBV12 + Pure populations of T cells experienced nearly complete cell loss after exposure to α-V5 and α-V12, respectively (Fig. 8H). These results suggested that the effects of all three BsAbs depended on the presence of the relevant TRBV or TRBC chain in treated T cells.

[0072] An exemplary BsAb molecule (Figure 1B) can be composed of one scFv arm that interacts with the TRBC or TRBV region (expressed only by a target T cell subset) and another scFv arm that interacts with the CD3ε subunit (expressed on all T cells). We next investigated whether such an exemplary BsAb molecule could induce bidirectional killing (where cross-linking by the BsAb induces activation of both "effector" and "target" T cells, thereby killing cross-linked "effector" T cells (expressing any TCR; Figure 2A)). For example, α-C1 cross-linking induces activation of TRBC1 + Activating T cells and conjugated TRBC2 +This would result in the killing of both TRBC1- and TRBC2-expressing T cells, leading to the observed near-complete T cell depletion (Figure 1C). Similarly, α-V5 or α-V12 would result in bidirectional killing of T cells that do not express TCRV5-5 or V12. In contrast, BsAbs used in strategies targeting non-T cell cancers are directed against cancer cell surface antigens, do not activate target cancer cells, and result in unidirectional killing. Three additional BsAbs were generated. These used the same TRBV or TRBC scFv described above, but replaced the α-CD3 scFv with the α-CD19 scFv (Figure 2B and Table 1). This demonstrates that TRBC1, TRBV5-5, or TRBV12 engagement mediates T cell activation and subsequent CD19 activation. + This allowed us to test whether the B-cell killing effect was sufficient for B-cell killing (Figure 2C). A conventional BsAb targeting CD19, in which an scFv against CD3 was linked to a CD19-specific scFv, was used as a positive control. +Coculture of target NALM6 B cells with normal T cells resulted in cytokine production, including interferon gamma (IFNγ), interleukin-2 (IL-2), tumor necrosis factor alpha (TNFα), and interleukin-10 (IL-10) (Figure 2D and Figure 9B). It also resulted in variable levels of target NALM6 B cell killing (Figure 2E), as well as expression of T cell activation markers, including CD25, inducible T cell costimulation (ICOS), and 4-1BB, and expression of exhaustion markers, including lymphocyte activation gene 3 (LAG-3) and programmed death 1 (PD-1) (Figure 9C). T cell cytokine production and NALM6 B cell cytotoxicity were dependent on NALM6 CD19 expression (Figure 2D, Figure 9B, and Figure 2E), as NALM6 CD19 knockout (Figure 9A) abolished these effects. In the presence of BsAb, no differences in IFNγ production or NALM6 B cell cytotoxicity were observed between wild-type NALM6 B cells and NALM6 B cells expressing lower levels of CD19 (Figure 9A, D, and E). To demonstrate the specificity of these effects, TRBC1 cells were isolated from the T cell pool before coculture with NALM6 B cells in the presence of BsAb. + , TRBV5 + or TRBV12 + We depleted T cells. These depleted T cells remained inactivated, as indicated by their inability to produce IFNγ after coculture with NALM6 B cells in the presence of α-V5-CD19 and α-V12-CD19 (Figure 2F). Similarly, depleted T cells were unable to kill NALM6 B cells (Figure 2H). Addition of α-V5-CD19 and α-V12-CD19 to TRBV5- and TRBV12-enriched human T cells restored IFNγ production and killing capacity to those of α-CD3-CD19- and α-C1-CD19-treated conditions (Figure 2, G and I).

[0073] Exposure to α-CD3-CD19 and α-C1-CD19 resulted in significantly higher IFNγ levels and NALM6 cell cytotoxicity than exposure to α-V5-CD19 and α-V12-CD19. There are two possible reasons for this observation. First, approximately 35–45% of human T cells express TRBC1, whereas 1.5–5% of normal T cells express TRBV5-5 or TRBV12 (Figure 1C,D). The resulting effector-to-target (E:T) ratio was therefore much higher with α-CD3-CD19 and α-C1-CD19 than with α-V5-CD19 and α-V12-CD19. It is also possible that the T cell activation potency of α-CD3 and α-TRBC1 scFvs was higher than that of α-TRBV5-5 or α-TRBV12 scFvs. This latter possibility is supported by the fact that TRBV5 in the presence of α-V5 or α-V12 + or TRBV12 + This was ruled out by evidence that NALM6 cells cocultured with enriched T cells resulted in IFNγ production and cytotoxicity comparable to that observed with α-CD3 and α-C1 BsAbs ( Fig. 2, G and I ).

[0074] Similar experiments were performed to demonstrate that α-C1 can mediate the death of TRBC2-expressing clonally generated T cells through bidirectional killing, even though these cells do not express TRBC1 (Figure 10A-D). α-C1 exposure induced IFNγ production in both TRBC1+ (Jurkat) and TRBC2+ (HPB-ALL) cells (Figure 10C). Depletion of the TRBC1+ T cell subset limited α-C1-induced IFNγ production in HPB-ALL cells (Figure 10C). Flow cytometry analysis also demonstrated α-C1-mediated HPB-ALL cell death using non-depleted T cells, while depletion of TRBC1+ T cells attenuated the effect (Figure 10D). α-C1 inhibited TRBC1 and normal TRBC2 expression on Jurkat cells. + Cross-linking of CD3 on T cells results in the release of residual normal TRBC2 +Since T cells were activated, depletion of normal TRBC1+ T cells did not affect the α-C1-induced IFNγ response to Jurkat cells (Figure 10C) or α-C1-mediated Jurkat cell killing (Figure 10D). We concluded that potent bidirectional killing can be mediated by BsAbs targeting TRBC1, TRBV5-5, or TRBV12. The reason why BsAbs targeting TRBV5-5 or TRBV12 can be used to target T cells expressing these receptors without depleting the majority of T cells is due to the low levels of TRBV5-5 in the normal T cell population. + or TRBV12 + The number of cells is TRBC1 + This is because the number of cells is much smaller than the number of cells.

[0075] TRBV-directed BsAb induces T cell cytokine responses against cancer cells in vitro Human T-cell cancer-derived cell lines have rearranged TCRβ genes and express clonal TRBVs. We observed that T-ALL-derived Jurkat, HPB-ALL, and CCRF-CEM T-cell lines retained cell surface TCR expression as assessed with anti-CD3 antibodies, whereas MOLT3 cells did not (Figure 11A). Jurkat and HPB-ALL cells also expressed surface TRBV12 and TRBV5-5, respectively (Figure 11B). To evaluate the activity of BsAbs against T-cell malignancies, normal T cells were cocultured with T-cell cancer cell lines in the presence or absence of different BsAbs.

[0076] Increased baseline IFNγ production in the absence of any cancer cells was observed after exposure to α-C1 and, to a lesser extent, α-V5 and α-V12 (Figure 3A). α-V5 and α-V12 were significantly associated with HPB-ALL (TRBV5-5), respectively. + In the presence of TRBV12-3 and Jurkat (TRBV12-3) cells, IFNγ secretion from T cells was increased above baseline. Basal IFNγ production in the absence of target cancer cells was higher than that of TRBV5-5, which is present in normal T cells. + and TRBV12 +To confirm whether this was due to a low proportion of T cells, we depleted these cells before exposure to BsAb. TRBV5- and TRBV12-depleted T cells failed to produce IFNγ in response to α-V5 and α-V12, respectively (Figure 3B). As a control for this experiment, we used TRBV5-5 + and TRBV12 + It was shown that T cell depletion did not affect IFNγ production in the presence of α-C1 BsAb (Figure 3B). In addition, TRBV5-depleted T cells suppressed IFNγ production in HPB-ALL (TRBV5-5) in the presence of α-C1 BsAb. + ) cells secreted IFNγ. Similarly, Jurkat (TRBV12-3) cells secreted IFNγ in the presence of α-V12. + TRBV12-depleted T cells cocultured with α-V5 and α-V12 cells also secreted IFNγ. This also indicated that the TRBV depletion process itself did not result in loss of normal T cell function. T cell activation via α-V5 and α-V12 was polyfunctional, accompanied by the release of multiple cytokines, including IFNγ, TNF-α, IL-2, interleukin-5 (IL-5), and granulocyte-macrophage colony-stimulating factor (GM-CSF) (Figure 3, C and D).

[0077] As a further control for the specificity of these BsAbs, we created isogenic cancer cells using CRISPR-based disruption of the TCR alpha and beta constant regions in both Jurkat and HPB-ALL cell lines. The resulting TCR knockout (KO) was confirmed by the loss of cell surface TRBV12 or TRBV5-5 (Figure 11B) and cell surface CD3 expression (Figure 4, C and D). After TCR-KO, when HPB-ALL cells were cocultured with normal T cells in the presence of α-V5, no significant increase in IFNγ or the other four cytokines tested was observed (Figure 3C). Similarly, little increase in cytokines was observed after coculture of TCR-KO Jurkat cells with normal T cells in the presence of α-V12 (Figure 3D).

[0078] TRBV-directed BsAb kills cancer cell lines in vitro To assess cytotoxicity, normal human T cells were cocultured with Jurkat or HPB-ALL cells in the presence of increasing concentrations of α-V12 or α-V5 BsAb (Figure 4A, B). Near-complete Jurkat and HPB-ALL cytotoxicity was observed with both α-V12 and α-V5 at a concentration of 0.01 nM (0.57 ng / mL). Cancer cell lines were also engineered to express GFP. GFP-expressing Jurkat cells were eliminated when cocultured with normal T cells in the presence of α-V12 (Figure 4C, E and Figure 12A). Exposure to α-V12 and normal T cells had no significant effect on TCR-KO Jurkat cells (Figure 4C, E and Figure 12A). Similarly, GFP-expressing HPB-ALL cells were also eliminated when cocultured with normal T cells in the presence of α-V5, and this elimination was reversed in TCR-KO HPB-ALL cells (Figure 4D, F and Figure 12A). As another control for this experiment, α-CD19 BsAb was shown to have no effect on either Jurkat or HPB-ALL cells when incubated with normal T cells (Figure 4C-F and Figure 12A). α-V12 also induced the expression of activation and exhaustion markers on normal human T cells in the presence of target Jurkat cells (Figure 12B). Similarly, α-V5 mediated the expression of activation and exhaustion markers on normal human T cells in the presence of target HPB-ALL cells (Figure 12C). Depletion of CD4 helper T cells from normal human T cells did not result in a loss of α-V12 or α-V5 activity (Figure 12D, E). In addition, the cytotoxic function of α-V12 and α-V5 was preserved after 96 h of incubation of the BsAbs with human serum before coculture (Fig. 12F).

[0079] To determine whether α-V12 affects T cells expressing TRBV family members other than TRBV12, Jurkat and normal T cells were cocultured in the presence of α-CD19 or α-V12 as described above. TRBV gene sequencing was then performed to measure the percentage of TRBV depletion in surviving cells. A dramatic reduction (98.9%) in TRBV12-3 levels was detected after exposure to α-V12 compared with exposure to α-CD19 (Figure 13A). Not surprisingly, the vast majority of TRBV12-3 signals were derived from Jurkat cells, not normal T cells. With the exception of TRBV12-4, which was reduced by 36.5%, other TRBV family members were unaffected (Figure 13A). A similar analysis was performed using HPB-ALL cells. A dramatic reduction (98.3%) in TRBV5-5 levels was detected after exposure to α-V5 compared with exposure to α-CD19 (Figure 13B). The overwhelming majority of TRBV5-5 signals were derived from HPB-ALL cells, not normal T cells. With the exception of TRBV5-6, which was again reduced by 91.6% (Figure 13B), other TRBV family members remained unaffected. The sequence of the TRBV5-5-directed scFv used in the α-V5 BsAb was derived from the antibody first raised against the TRBV5-5 antigen. Therefore, given that TRBV5-5 and TRBV5-6 are the most similar among TRBV5 family members, it was not surprising that TRBV5-6-expressing T cells were affected by α-V5 exposure (Figures 14A and 14B). Sequence alignment of TRBV5 family members revealed that amino acid residues D20, D81, and L101 were common to both TRBV5-5 and TRBV5-6 but distinct from other TRBV5 members, and that differences at residues 81 and 101 in other TRBV5 family members also resulted in major charge differences (Fig. 14C ).

[0080] TRBV-directed BsAb kills patient-derived T-ALL cells in vitro Primary malignant cells were collected from T-ALL patients. Flow cytometry revealed that two patients (patients 1 and 2) had significant TRBV12 expression, suggesting the presence of monoclonal cancer cells.+ We identified a population with α-V12-dependent IFNγ expression (Figure 5A). Co-culture of T-ALL cells from patients 1 and 2 with normal T cells in the presence of α-V12 led to significant IFNγ secretion (Figure 5B) and expression of activation and exhaustion markers on normal human donor T cells (Figure 5C). HLA-A3 expression was used to distinguish patient-derived T-ALL cells from normal T cells derived from two healthy human donors (Figure 5D). T cells from donor 2 (HLA-A3 + ) and patient 1 (HLA-A3 - Co-culture of donor 1 (HLA-A3) malignant cells with α-V12 demonstrated depletion of patient-derived malignant cells (Figure 5E, F). - ) T cells and patient 2 (HLA-A3 + Coculture with malignant cells also demonstrated depletion of malignant cells. In both cases, normal human T cells were relatively unaffected by exposure to α-V12 (Fig. 5E, F), as the proportion of TRBV12-expressing cells among normal T cells was low (Fig. 1C, D).

[0081] TRBV-directed BsAb kills cancer cells in vivo To assess in vivo efficacy, luciferase-expressing Jurkat or HPB-ALL cancer cells were transfected with NOD.Cg-Prkdc scid Il2rg tm1WjlTwo disseminated xenograft models were established by intravenous injection into / SzJ(NSG) mice (Figure 6, A–C). All mice also received human T cells via intravenous injection. For the Jurkat model, α-V12 BsAb was delivered via an intraperitoneal pump starting 4 days after inoculation of Jurkat and normal human T cells, by which time Jurkat cells had already spread extensively (Figure 6, A and B). The intraperitoneal pump was able to maintain significant serum concentrations of α-V12 and α-V5 for at least 2 weeks after implantation (Figure 15A). Bioluminescence imaging (BLI) demonstrated a significant tumor burden reduction in mice treated with α-V12 (Figure 6, B and D). Two controls, one against the BsAb and one against the cells, were used to demonstrate the specificity of this reduction. BsAb control: When Jurkat cancer-bearing mice were treated with α-CD19 instead of α-V12, tumor burden, as assessed by BLI, was significantly higher (Figure 6, B and D). Cell control: In mice bearing disseminated cancer derived from Jurkat TCR-KO cells, tumor burden was significantly higher after treatment with α-V12 compared to mice bearing WT Jurkat cells (Figure 6, B and D). A second disseminated cancer model was used to demonstrate the reproducibility of these in vivo results. The experimental approach was identical to that described for the Jurkat cell model, except that HPB-ALL cells were used instead of Jurkat cells and α-V5 was used instead of α-V12 (Figure 6, A and C). Again, BLI showed a significant decrease in luminescence in mice treated with α-V5 (Figure 6, C and D). Similar treatment of mice bearing disseminated cancer derived from α-CD19 or HPB-ALL TCR-KO cells also showed tumor growth similar to that observed in the Jurkat model (Figure 6, C and D). Flow cytometry analysis of mouse blood 19 days after cancer cell inoculation (15 days after BsAb treatment was initiated) revealed that all treatment groups retained normal human T cells (Figure 6, E and F). In addition, circulating Jurkat and HPB-ALL leukemia cells were abundant in α-CD19-treated mice (Figure 6, E and F).In stark contrast, α-V12- and α-V5-treated mice had a dramatic reduction in circulating leukemic cells in these experiments (Figure 6, E and F). This reduction in circulating leukemic cells was associated with a significant survival benefit for both α-V12- and α-V5-treated mice (Figure 6, G and H). α-CD19-treated mice developed hind leg paralysis and required euthanasia. Jurkat or HPP-ALL cancer-bearing mice treated with α-V12 or α-V5, respectively, did not develop hind leg paralysis. These mice eventually died (Figure 6, G and H) and displayed typical features of graft-versus-host disease (GVHD) at the time of death. However, if such an approach were used in humans, only BsAbs, not T cells, would need to be administered. In human T-cell cancers, an additional challenge is that malignant T cells often outnumber healthy effector T cells. To determine whether lower numbers of human effector T cells could sufficiently eradicate T cell tumors in vivo, 0.5 × 10 were administered to NSG mice. 6 2.5 × 10 human T cells 6 The α-V12 and α-V5 mice were co-injected with α-V12 or α-V5 tumor cells (Fig. 15B). BLI showed significant tumor burden reduction with both α-V12 and α-V5 treatment (Fig. 15C-E). α-V12 and α-V5 treatment also led to elevated IFNγ and TNFα cytokine production (Fig. 15F, G), along with the expression of T cell activation and exhaustion markers on normal human T cells (Fig. 15H, I).

[0082] Collectively, these results demonstrate that TRBV-targeted BsAbs can deplete clonal cancer T cells in vitro and in vivo while sparing the majority of normal T cells. Thus, TRBV-targeted BsAbs can be used to treat T cell cancers while avoiding treatment-related immunosuppression.

[0083] method Cell lines and primary human T cells Jurkat (Clone E6-1), CCRF-CEM, MOLT-3 (ATCC, Manassas, VA), HPB-ALL (DSMZ, Germany), and NALM6 cells were cultured in RPMI-1640 (ATCC, 30-2001) supplemented with 10% HyClone fetal bovine serum (FBS, GE Healthcare SH30071.03, Chicago, IL) and 1% penicillin-streptomycin (ThermoFisher Scientific, Waltham, MA). HEK293FT (ThermoFisher Scientific, Waltham, MA) cells were cultured in DMEM (ThermoFisher Scientific, 11995065) supplemented with 10% FBS, 2 mM GlutaMAX (ThermoFisher Scientific, 35050061), 0.1 mM MEM non-essential amino acids (ThermoFisher Scientific, 11140050), 1% penicillin-streptomycin, and 500 μg / mL Geneticin (ThermoFisher Scientific, 10131027). PBMCs were isolated from leukapheresis samples (Stem Cell Technologies, Vancouver, BC or Astarte Biologics, Bothell, WA) by Ficoll-Paque Plus (GE Healthcare, GE17-1440-02) density gradient centrifugation. Human T cells were expanded from PBMCs by adding either 15 ng / mL of anti-human CD3 antibody (clone OKT3, BioLegend, San Diego, CA, 317325) or Human T-Activator CD3 / CD28 Dynabeads (ThermoFisher Scientific, 11131D) at a bead:cell ratio of 1:5 for 3 days.T cells were cultured in RPMI-1640 containing 10% FBS, 1% penicillin-streptomycin, 100 IU / mL recombinant human IL-2 (aldesleukin, Prometheus Therapeutics and Diagnostics, San Diego, CA), and 5 ng / mL recombinant human IL-7 (BioLegend, 581906).

[0084] Cell staining, flow cytometry, and cell sorting Cells were cultured at 1 × 10 in flow staining buffer (PBS containing 0.5% BSA, 2 mM EDTA, 0.1% sodium azide) or flow sorting buffer (PBS containing 4% FBS). 6The cells were suspended at 100 cells / mL and incubated with the appropriate antibody for 30 minutes on ice. The antibodies used were: Brilliant Violet (BV)-711 anti-human CD3 (clone OKT3 BioLegend# 317328); APC-anti-human CD45 (clone HI30 BioLegend# 304012); APC-anti-human CD19 (clone HIB19, BioLegend# 302212), PE-anti-human CD4 (clone RPA-T4, BioLegend# 300508), APC-anti-human CD8 (clone SK1, BioLegend# 344722), PE-anti-human Cβ1 TCR (clone JOVI.1 BD# 565776), PE-anti-human HLA-A3 (clone GAP.A3 BD# 566605), PE-TCR vβ5.1 (clone ImmU157), PE-TCR Vβ5.3 (clone 3D11), PE-TCR Vβ5.2 (clone 36213), FITC-TCR Vβ8 (clone 56C5.2 Beckman Coulter), BV-421-anti-human CD25 (Biolegend #302630), APC-anti-human ICOS (Biolegend #313510), BV-750-anti-human 41BB (Biolegend #309844), BV-421-anti-human LAG3 (Biolegend #369314), and APC-anti-human PD1 (Biolegend #329908). Stained cells were analyzed using an LSRII flow cytometer or sorted using a BD FACSAria II (Becton Dickinson, Mansfield, MA). Gating for single live cells was performed using a live / dead dye (LIVE / DEAD Fixable Near-IR, L10119; Aqua Dead Cell Stain Kit L34957, Invitrogen) and forward and side scatter characteristics. CellTrace Violet staining (ThermoFisher C34557) was performed according to the manufacturer's instructions.

[0085] Depletion or enrichment of TRBCs, TRBV, and CD4 For depletion of TRBC1 T cells, 1 x 10 8 1 × 10 normal T cells were stained with PE-mouse anti-human Cβ1 TCR (final concentration 1 μg / ml), followed by sorting of PE-negative (TRBC1-depleted) cells. For depletion or enrichment of TRBV5 T cells, 1 × 10 8 1 × 10 normal T cells were stained with PE-TCR Vβ5.3 (which binds TRBV5-5) and PE-TCR Vβ5.2 (which binds TRBV5-6), followed by sorting for PE-negative (TRBV5-depleted) or PE-positive (TRBV5-enriched) cells. For depletion or enrichment of TRBV12 T cells, 1 × 10 normal T cells were stained with PE-TCR Vβ5.3 (which binds TRBV5-5) and PE-TCR Vβ5.2 (which binds TRBV5-6). 8 Normal T cells were stained with FITC-TCR Vβ8 (which binds to TRBV12-3 and TRBV12-4 T cells) followed by sorting for FITC-negative (TRBV12-depleted) or FITC-positive (TRBV12-enriched) cells. Alternatively, EasySep PE Positive Selection Kit II (StemCell Technologies, 17684) was used for cell isolation. For CD4 T cell depletion, normal T cells were stained with PE-anti-human CD4 followed by isolation of CD4-negative (CD4-depleted) cells using EasySep PE Positive Selection Kit II.

[0086] Bispecific antibody production, purification, and stability The α-TRBV5-5, α-TRBV12, α-TRBC1, and α-CD19 scFv sequences (Table 1) were synthesized by GeneArt (ThermoFisher Scientific). The scFv sequences were expressed as single-chain diabody formats using the following N-to-C-terminal format: IL-2 signal sequence, anti-TRBV / TRBC / CD19 variable light chain (VL), GGGGS linker (SEQ ID NO:25), α-CD3 variable heavy chain (VH), (GGGGS)3 linker (SEQ ID NO:26), α-CD3 VL, GGGGS linker (SEQ ID NO:25), anti-TRBV / TRBC / CD19 VH, and a 6xHIS tag, and cloned into the pcDNA3.4 vector (ThermoFisher Scientific). BsAbs were expressed and purified by the JHU Eukaryotic Tissue Culture Core Facility or by GeneArt. For BsAb expression, 1 mg of plasmid was added to 2 × 10 cells in a 1:3 ratio with polyethyleneimine (PEI) in a 1 L suspension culture of HEK293F cells from the JHU Eukaryotic Tissue Culture Core Facility. 6 The cells were transfected at a density of 1000 cells / mL. Freshly transfected HEK293F cells were grown in Freestyle293 expression medium at 37°C, 170 rpm, and 5% CO2 for 5 days. The medium was then collected by centrifugation, filtered through a 0.22 μm unit, and the BsAb was purified using Nickel affinity chromatography. For this, 2 mL of Ni-NTA His-Bind (Millipore Sigma, 70666-6) resin was added to the filtered supernatant and incubated overnight at 4°C on an orbital shaker. The supernatant-resin mixture was loaded onto a gravity chromatography column (Econo-Pac). The fragments were captured using Chromatography Columns (7321010, Bio-Rad, Hercules, CA) and washed with 20 mM imidazole (GE Healthcare, 45-000-007) in phosphate-buffered saline (PBS). The desired BsAb was eluted with 500 mM imidazole and desalted into PBS using a 7k MWCO Zeba Spin Desalting Column (ThermoFisher Scientific, 89883). Protein was quantified via SDS-PAGE gel electrophoresis (Mini-PROTEAN TGX Stain-Free Precast Gel, Bio-Rad, 4568095) and / or using the BCA protein assay (Pierce, ThermoFisher, 23225). Protein was stored at -80°C with 7% glycerol. Alternatively, BsAbs were produced by GeneArt in Expi293 and purified by size-exclusion chromatography using a HisTrap column (GE Healthcare, 17-5255-01) followed by a HiLoad Superdex 200 26 / 600 column (GE Healthcare, 28989336). Analytical chromatography was performed using a TSKgel G3000SWxl column (TOSOH Bioscience) with a running buffer of 50 mM sodium phosphate, pH 7, and 300 mM sodium chloride at a flow rate of 1.0 mL / min. Coomassie blue staining of BsAbs (ThermoFisher Scientific, 20278) and anti-histidine Western blot analysis were performed by GeneArt using an anti-6x-His tag antibody (ThermoFisher Scientific, MA1-21315).

[0087] The thermal stability of α-V12 and α-V5 BsAbs was assessed by differential scanning fluorimetry, which monitors the fluorescence of dyes that bind to hydrophobic regions of proteins exposed by temperature-induced denaturation. Reaction mixtures (20 μL) were prepared by mixing 2 μL of purified α-V12 or α-V5 BsAb at a concentration of 1 mg / mL in phosphate-buffered saline (PBS, Gibco, 10010023), pH 7.4, with 2 μL of 50X SYPRO orange dye (Invitrogen S6650) in a white, low-profile, 96-well, non-skirted polymerase chain reaction plate (Bio-Rad, MLL9651). The plate was sealed with light-transmitting film and centrifuged at 1000 × g for 30 seconds. A thermal scan was performed from 25 to 100°C (with a temperature ramp of 1°C / min) using a CFX9 Connect real-time polymerase chain reaction instrument (Bio-Rad). Using CFX Manager Software (Bio-Rad), determine the protein unfolding / melting temperature (T) from the maximum of the negative first derivative of the melting curve. m ) was calculated. Serum stability was assessed by incubating BsAbs with human serum (Millipore Sigma #H4522) at a concentration of 0.05 μg / mL for 0, 24, and 96 hours in a 37°C incubator. At each time point, the human serum-BsAb mixture was collected and frozen at -80°C until BsAb functional analysis by co-culture assay.

[0088] CRISPR gene editing We used the Alt-R CRISPR system (Integrated DNA Technologies, Coralville, IA) to generate TCR knockout Jurkat and HPB-ALL cell lines, as well as CD19 knockout and CD19-low expressing NALM6 clones. TIFF2023551535000006.tif5128, TRB constant region Alt-R CRISPR Cas9 crRNA targeting TIFF2023551535000007.tif4128 and Alt-R CRISPR-Cas9 tracrRNA (IDT, 1072533) were resuspended at 100 μM in Nuclease-Free Duplex Buffer. According to the manufacturer's instructions, the crRNA and tracrRNA were duplexed at a 1:1 molar ratio at 95°C for 5 minutes, followed by slow cooling to room temperature. The duplex RNA was then mixed with Cas9 nuclease at a 1.2:1 molar ratio for 15 minutes. A total of 40 pmoles of gRNA-complexed Cas9 RNP was mixed with 500,000 cells in 20 μL of OptiMEM (ThermoFisher, 51985091). The mixture was loaded into a 0.1 cm cuvette (Bio-Rad) and electroporated at 90 V for 15 ms using ECM 2001 (BTX, Holliston, MA). Cells were immediately transferred to complete growth medium and cultured for 7 days. Single-cell clones were established by limiting dilution, and genomic DNA was isolated using the Quick-DNA 96 Kit (Zymo Research, Irvine, CA, D3010). Regions flanking the CRISPR cleavage site were PCR amplified (TCRα forward primer: TIFF2023551535000008.tif4128, reverse primer: TIFF2023551535000009.tif4128; TCRβ forward primer: TIFF2023551535000010.tif4128, reverse primer: TCRα- / β- clones were selected by Sanger sequencing (TIFF2023551535000011.tif4128). TRA and TRB chain gene disruption was confirmed by loss of surface CD3 expression.

[0089] Alt-R CRISPR sgRNA to generate CD19 knockout and CD19-low NALM6 clones TIFF2023551535000012.tif4128 was complexed with Cas9 nuclease (IDT) at a 2:1 molar ratio for 15 minutes at room temperature. 50 pmoles of Cas9 RNP was then mixed with 200,000 NALM6 cells resuspended in 20 μL of SF buffer (Lonza) and electroporated in 16-well cuvette strips using a 4D Nucleofector X-unit (Lonza) with pulse code CV-104. Cells were cultured in complete growth medium for 7 days before dilution plating to select individual clones. Clonal cell surface CD19 levels were characterized by flow cytometry staining with an anti-human CD19 antibody.

[0090] Retroviral transduction Non-tissue culture-treated plates were coated with 100 μL of 20 μg / mL RetroNectin (Clontech Takara, Mountain View, CA, T202) in PBS overnight at 4°C, then blocked with 10% FBS for 1 hour at room temperature. Retrovirus (RediFect Red-FLuc-GFP, PerkinElmer CLS960003) and 2 × 10 5 Target cells were added to each well and centrifuged at 2000 x g for 1 hour at 20°C. Plates were incubated at 37°C for 2 days, after which cells were expanded into 6-well plates. Transduced cells were isolated based on GFP expression by FACS (BD FACSAria II).

[0091] TCR sequencing Total RNA was isolated from samples using Qiagen AllPrep DNA / RNA Micro kits (Qiagen, 80284). RNA quality was verified using an Agilent TapeStation system. TCR sequencing libraries were prepared using the 5' RACE (rapid amplification of cDNA ends) method, which consisted of a cDNA synthesis step followed by two PCR steps using gene-specific primers for the TCR β constant region. Libraries were sequenced using the Illumina MiSeq platform. Reads were analyzed using the MIGEC, MiXCR, and VDJ tools. Clonotype frequencies were calculated as the percentage of UIDs (unique molecular identifier barcodes) representing the clonotypes among all UIDs in the sample. The following non-functional TRBVs (listed as pseudogenes or open reading frames in IMGT) were excluded from the analysis: TRBV1, TRBV3-2, TRBV5-2, TRBV5-3, TRBV5-7, TRBV6-7, TRBV7-1, TRBV7-5, TRBV8, TRBV12-1, TRBV12-2, TRBV21, TRBV22, TRBV23-1, TRBV26.

[0092] TRBV sequence and structural alignment The structures of PDB IDs 5BRZ, 6EH5, 4P4K, and 4QRR were structurally aligned, and residues 2–95, corresponding to the TCR beta variable region of TRBV 5.1, were extracted from 5BRZ. To model TRBVs 5.4, 5.5, 5.6, and 5.8, in silico mutations were performed at positions 81 and 101 using Coot. Figures were rendered with PyMOL (v2.2.3, Schrodinger, LLC, New York, NY). Alignments of related TRBV sequences were performed using ClustalOmega and displayed using Espript.

[0093] co-culture Co-cultures were performed using 96-well flat-bottom tissue culture treated plates, with each well containing 5 x 10 cells in a total volume of 100 µL of RPMI medium. 45 × 10 normal human T cells (effector cells) 4 The cocultures were set up to contain 100 target cells (as indicated in the text) and BsAb (at the concentrations specified in the text). The cocultures were incubated at 37°C for 17 hours. Supernatants were assayed for cytokines using a Human IFN-gamma Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, SIF50C), a Human IL-2 Quantikine ELISA Kit (R&D Systems, S2050), a Human TNF-alpha Quantikine ELISA Kit (R&D Systems, STA00D), a Human IL-10 Quantikine ELISA Kit (R&D Systems, S1000B), or a Luminex assay (13-plex-Immunology Multiplex Assay, MilliporeSigma, USA, HMHEMAG-34K) performed on a Bio-Plex 200 system (Bio-Rad). Luciferase-expressing target cells were assayed for cell viability using the Steady-Glo luciferase assay (E2510, Promega, Madison, WI) according to the manufacturer's instructions. Viability was calculated as the ratio of luminescence signal relative to the no-antibody or control antibody condition: (luminescence of antibody wells) / (luminescence of no-antibody or control antibody wells). Alternatively, tumor cells were quantified by flow cytometry-based GFP expression (for GFP-expressing tumor cell lines) or distinct HLA expression (for patient-derived tumor cells). In experiments to detect the effect of BsAbs on healthy T cells in the absence of target tumor cells, 1 × 10 6 Normal human T cells were incubated with BsAb (at the concentrations specified in the text) in a total volume of 1 mL of RPMI medium and incubated for 17 hours at 37°C. Viable T cells were quantified by counting trypan blue-stained cells on a hemocytometer.

[0094] Collection of T-ALL patient samples T-cell cancer patient samples were collected in accordance with the Hematologic Malignancy Cell Bank Protocol (J0969) or the Johns Hopkins Pediatric Leukemia Bank Protocol (J0968), approved by the Johns Hopkins Institutional Review Board (IRB: NA_00028682 and NA_00028682).

[0095] Animal experiments Six- to eight-week-old female NOD.Cg-Prkdc mice were obtained from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Animal Resources facility. scid Il2rg tm1Wjl / SzJ(NSG) mice were maintained according to JHU Animal Care and Use Committee-approved research protocol MO18M79. Cancer cell lines and human T cells were injected via the tail vein. Two-week microosmotic pumps (Model 1002, ALZET, Cupertino, CA) were loaded with BsAb as indicated in the text using a 30G needle. Pumps were placed into the peritoneal cavity of each mouse using aseptic surgery. For survival studies, animals were followed for up to 80 days or sacrificed when they developed evidence of paralysis or GVHD (hunchback posture, piloerection, scaling or peeling of the skin, decreased activity). Mouse bioluminescence was measured using an IVIS system (PerkinElmer, USA). Before imaging, mice were anesthetized using inhaled isoflurane in an induction chamber. After induction, mice received an intraperitoneal injection of luciferin (150 μl, RediJect D-Luciferin Ultra Bioluminescent Substrate, PerkinElmer, 770505) and were placed in the imaging chamber 5 minutes later. Luminescent images were analyzed using Living Image software (version 4.7.2, PerkinElmer). For flow-based detection of tumor cells and normal human T cells from mouse blood, 100 μL of blood was collected by cheek bleed into EDTA-treated microvessels (Sarstedt Inc, NC9299309). The blood was then incubated with 1 mL of ACK lysis buffer (Quality Biological, 118-156-721) for 10 minutes and resuspended in flow staining buffer with mouse and human TrueStain FcX Fc receptor blocking solution (BioLegend, 101320, 422302) and cell surface staining antibodies. 10 μL of counting beads (Precision Count Beads, BioLegend, 424902) were added to an equal volume (300 μL) of cell suspension in each tube. Based on 500 beads per sample, tumor cells (GFP + , CD3 + ) or T cells (GFP - , CD3+ The number of IgG antibodies was counted. For cytokine and BsAb detection, blood from mice was collected into Eppendorf tubes, allowed to clot at room temperature for 30 minutes, and then centrifuged at 1000 × g for 5 minutes at 4°C. Serum was collected and stored at -80°C until cytokine ELISA (according to the manufacturer's instructions) or BsAb ELISA. For BsAb ELISA, mouse serum was incubated in biotinylated recombinant human CD3 epsilon & CD3 delta (Acro Biosystems, DE, USA, # CDD-H52W4)-coated streptavidin plates (R&D Systems, #CP004), followed by detection using an HRP-conjugated anti-human kappa light chain antibody (ThermoFisher Scientific, #A18853).

[0096] statistical analysis Data were summarized using the mean ± standard error of the mean. Student's t-test was used to compare mean differences between two samples for normally distributed variables. For three or more groups, one-way ANOVA and Tukey's multiple comparison test (when comparing all groups), Dunnett's test (when comparing a test group with one control group), or Sidak's test (when comparing two selected groups) were used with α = 0.05. The Kaplan-Meier method was used to generate median survival times, and hazard ratios were estimated by the log-rank test. Prism version 8.0 software (GraphPad, La Jolla, CA) was used for statistical analysis and graphing.

[0097] Sequence Listing TIFF2023551535000013.tif135128TIFF2023551535000014.tif215159TIFF2023551535000015.t if216159TIFF2023551535000016.tif216158TIFF2023551535000017.tif223159TIFF2023551535 000018.tif223158TIFF2023551535000019.tif223158TIFF2023551535000020.tif22339TIFF202 3551535000021.tif223157TIFF2023551535000022.tif215159TIFF2023551535000023.tif84157

[0098] Other Aspects While the present invention has been described in conjunction with the detailed description thereof, it is to be understood that the foregoing description is intended to be illustrative of the invention and not limiting of its scope, which is defined by the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

Claims

1. a first polypeptide comprising a first antigen-binding domain capable of binding to a T cell receptor beta chain variable (TRBV) polypeptide; a second polypeptide comprising a second antigen-binding domain capable of binding to the T cell co-receptor polypeptide; 2. A bispecific molecule comprising:

2. The bispecific molecule of claim 1, wherein the first polypeptide is selected from the group consisting of a single-chain variable fragment (scFv), an antigen-binding fragment (Fab), an F(ab')2 fragment, and biologically active fragments thereof.

3. The TRBV polypeptide is a TRBV2 polypeptide, a TRBV3-1 polypeptide, a TRBV4-1 polypeptide, a TRBV4-2 polypeptide, a TRBV4-3 polypeptide, a TRBV5-1 polypeptide, a TRBV5-4 polypeptide, a TRBV5-5 polypeptide, a TRBV5-6 polypeptide, a TRBV5-8 polypeptide, a TRBV6-1 polypeptide, a TRBV6-2 polypeptide, a TRBV6-3 polypeptide, a TRBV6-4 polypeptide, a TRBV6-5 polypeptide, a TRBV6-6 polypeptide, a TRBV6-8 polypeptide, a TRBV6-9 polypeptide, a TRBV7-2 polypeptide, a TRBV7-3 polypeptide, a TRBV7-4 polypeptide, a TRBV7-6 polypeptide, a TRBV7-7 polypeptide, a TRBV7-8 polypeptide, a TRBV7-9 polypeptide, a TRBV9 polypeptide, 3. The bispecific molecule of any one of claims 1 to 2, wherein the bispecific molecule is selected from the group consisting of a TRBV10-1 polypeptide, a TRBV10-2 polypeptide, a TRBV10-3 polypeptide, a TRBV11-1 polypeptide, a TRBV11-2 polypeptide, a TRBV11-3 polypeptide, a TRBV12-2 polypeptide, a TRBV12-3 polypeptide, a TRBV12-4 polypeptide, a TRBV12-5 polypeptide, a TRBV13 polypeptide, a TRBV14 polypeptide, a TRBV15 polypeptide, a TRBV16 polypeptide, a TRBV18 polypeptide, a TRBV19 polypeptide, a TRBV20-1 polypeptide, a TRBV24-1 polypeptide, a TRBV25-1 polypeptide, a TRBV27 polypeptide, a TRBV28 polypeptide, a TRBV29-1 polypeptide, and a TRBV30 polypeptide.

4. The bispecific molecule of claim 3, wherein the TRBV polypeptide is a TRBV5-5 polypeptide.

5. A first antigen-binding domain capable of binding to a TRBV5-5 polypeptide, V having the amino acid sequence shown in SEQ ID NO: 1 L CDR1, V having the amino acid sequence shown in SEQ ID NO:2 LCDR2, and V having the amino acid sequence shown in SEQ ID NO:3 L a light chain comprising a CDR3; V having the amino acid sequence shown in SEQ ID NO:4 H CDR1, V having the amino acid sequence shown in SEQ ID NO:5 H CDR2, and V having the amino acid sequence shown in SEQ ID NO:6 H Heavy chain, including CDR3 5. The bispecific molecule of claim 4, comprising:

6. The bispecific molecule of claim 5, wherein the light chain comprises the amino acid sequence set forth in SEQ ID NO:7 and the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:

8.

7. The bispecific molecule of claim 5, wherein the light chain comprises the amino acid sequence set forth in SEQ ID NO: 38 and the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:

39.

8. The bispecific molecule of claim 3, wherein the TRBV polypeptide is a TRBV12 polypeptide.

9. A first antigen-binding domain capable of binding to a TRBV12 polypeptide, V having the amino acid sequence shown in SEQ ID NO:9 L CDR1, V having the amino acid sequence shown in SEQ ID NO: 10 L CDR2, and V having the amino acid sequence shown in SEQ ID NO: 11 L a light chain comprising a CDR3; V having the amino acid sequence shown in SEQ ID NO: 12 H CDR1, V having the amino acid sequence shown in SEQ ID NO: 13 H CDR2, and V having the amino acid sequence shown in SEQ ID NO: 14 H Heavy chain, including CDR3 The bispecific molecule of claim 8, comprising:

10. The bispecific molecule of claim 9, wherein the light chain comprises the amino acid sequence set forth in SEQ ID NO: 15 and the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:

16.

11. The bispecific molecule of claim 9, wherein the light chain comprises the amino acid sequence set forth in SEQ ID NO: 40 and the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:

41.

12. The bispecific molecule of claim 1, wherein the second polypeptide is selected from the group consisting of a single-chain variable fragment (scFv), an antigen-binding fragment (Fab), an F(ab')2 fragment, and biologically active fragments thereof.

13. 13. The bispecific molecule of claim 1 or claim 12, wherein the T cell co-receptor polypeptide is a cluster of differentiation 3 (CD3) polypeptide.

14. a second antigen-binding domain capable of binding to a CD3 polypeptide, V having the amino acid sequence shown in SEQ ID NO: 17 L CDR1, V having the amino acid sequence shown in SEQ ID NO: 18 L CDR2, and V having the amino acid sequence shown in SEQ ID NO: 19 L a light chain comprising a CDR3; V having the amino acid sequence shown in SEQ ID NO: 20 H CDR1, V having the amino acid sequence shown in SEQ ID NO: 21 H CDR2, and V having the amino acid sequence shown in SEQ ID NO: 22 H Heavy chain, including CDR3 The bispecific molecule of claim 13, comprising:

15. The bispecific molecule of claim 14, wherein the light chain comprises the amino acid sequence set forth in SEQ ID NO: 23 and the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:

24.

16. 16. A pharmaceutical composition comprising the bispecific molecule of any one of claims 1 to 15 for treating a mammal having a T-cell cancer.

17. 17. The pharmaceutical composition of claim 16, wherein the mammal is a human.

18. The pharmaceutical composition of any one of claims 16 to 17, wherein the T cell cancer is a clonal T cell cancer.

19. 18. The pharmaceutical composition of any one of claims 16-17, wherein the T-cell cancer is selected from the group consisting of acute lymphoblastic leukemia (ALL), peripheral T-cell lymphoma (PTCL), angioimmunoblastic T-cell lymphoma (AITL), T-cell prolymphocytic leukemia (T-PLL), adult T-cell leukemia / lymphoma (ATLL), enteropathy-associated T-cell lymphoma (EATL), monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), follicular T-cell lymphoma (FTCL), nodal peripheral T-cell lymphoma (nodal PTCL), cutaneous T-cell lymphoma (CTCL), anaplastic large cell lymphoma (ALCL), T-cell large granular lymphocytic leukemia (T-LGL), extranodal NK / T-cell lymphoma (NKTL), and hepatosplenic T-cell lymphoma.

20. 20. The pharmaceutical composition of any one of claims 16 to 19, wherein said cancer cells in said mammal are reduced by at least 95 percent.

21. 20. The pharmaceutical composition of any one of claims 16 to 19, which is effective to improve the survival time of said mammal.

22. 22. The pharmaceutical composition of claim 21, wherein the survival time of the mammal is improved by at least 37.5 percent.

23. 1. A pharmaceutical composition for treating a mammal having celiac disease, comprising: a first polypeptide comprising a first antigen-binding domain capable of binding to a T cell receptor beta chain variable (TRBV) polypeptide; a second polypeptide comprising a second antigen-binding domain capable of binding to the T cell co-receptor polypeptide; A pharmaceutical composition comprising a bispecific molecule comprising:

24. 24. The pharmaceutical composition of claim 23, wherein the mammal is a human.

25. The pharmaceutical composition of claim 23 or claim 24, wherein the TRBV polypeptide is selected from the group consisting of TRBV4, TRBV6, TRBV7, TRBV9, TRBV20, and TRBV29, and the T cell coreceptor polypeptide is a CD3 polypeptide.

26. The pharmaceutical composition of claim 23 or claim 24, wherein the TRBV polypeptide is selected from the group consisting of TRBV6-1, TRBV7-2, TRBV9-1, TRBV20-1, and TRBV29-1, and the T cell co-receptor polypeptide is a CD3 polypeptide.